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Abstract

Murine model organisms are an essential tool in the scientific community quest to
decipher the molecular etiology of human diseases. Currently, several methods are
used to induce or reproduce human diseases in mouse models using advanced genetic
engineering techniques to mutate the wild-type genes. We utilized the Baygenomics
gene-trap method to study the effects of two mammalian genes: FOXN3 and CHD2.
The Forkhead Box (FOX) family of transcription factors shares a common DNA-binding
domain and has been associated with organ development, differentiation, cell growth
and proliferation, and cancer. Meanwhile, the CHD (Chromodomain helicase DNA
binding protein) family of proteins is known to be involved in chromatin remodeling and
regulation of gene expression. Phenotypic analysis of Foxn3 mutant animals revealed
its indispensible role in craniofacial and embryonic development, embryonic lethality,
expression of bone morphogenetic proteins, and spontaneous development of cancers
in heterozygous and homozygous mutant mice. Preliminary evaluation of molecular
mechanisms of FOXN3 signifies deregulation of cell-cycle checkpoint proteins Cyclin-B1
and CDK2 as the underlying etiology of tumors. Chd2 mutant mice exhibit spontaneous
thymic and splenic lymphomas and reduced lifespan which can be restored through
Chd2 re-expression in the thymus. At the molecular level, CHD2 deficiency reduces
Puma (p53-upregulated modulator of apoptosis) induction after DNA damage in mouse
thymocytes and HCT116 cells. Additionally, CHD2 is enriched at the Puma locus after
DNA damage. CHD2-deficient cells also exhibit global reduction of active transcription
markers H3K9-Acetylated and H4K8-Acetylated.
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Chapter I
The Utilization of Animal Models to Study Genes in Development and Disease
Introduction to Model Organisms
A model organism is a class of living organisms extensively used to identify or
perform in-depth studies on a biological process. Because many aspects of biology are
similar in most or all organisms, it is typically easier to study a particular aspect of a
biological process in one organism over the others. Selection of proper model organism
to conduct research is of utmost importance; principal investigators must select the
model organism depending on the echelon of biology pursued, as in macro- versus
micro- biology. The most popular model organisms have strong advantages to perform
experimental research, such as rapid development with short life cycles, small adult
size, constant availability, ease of handling, and common usage by other scientists (1).
Model organisms can be generally classified into three main categories: mammalian
models, non-mammalian models, and plants. For this dissertation, we will focus heavily
on mammalian models and some non-mammalian models; plant model organisms such
as Arabidopsis thaliana will not be discussed. Non-mammalian model organisms
include members of all three domains of modern taxonomy: Archaea, Bacteria, and
Eukarya. Mammalian model organisms represent the Mammalia class within the
Animalia kingdom of the Eukarya domain.
Non-mammalian Model Organisms
Non-mammalian model organisms spread over the three domain of living
organisms and vary greatly in tissue complexity and even cellular components.
However, they are very advantageous to study fundamental cellular processes that are
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inherently conserved in higher organisms. On genetic basis, our understanding of gene
function is typically inferred by comparing the phenotypic consequences of mutating the
canonical “wild-type” gene in one organism and relating this phenotype to mutants of
orthologous genes in a different organism (2). One of the great advantages to using
non-mammalian model organisms is the availability of whole-genome sequencing for
many of these species, thus enabling scientists to compare genomic sequences and
conservation of orthologous genes. Many scientists work on specific organisms or
genus to uncover specialized processes; nevertheless, most scientists choose one of
the NIH (National Institute of Health) supported model organisms.
Escherichia coli. E. coli is a prokaryotic organism (Bacteria domain) widely used for
basic scientific research. E. coli has been widely used to obtain basic biological
processes including information on molecular biology and gene regulation, metabolic
pathways and biochemistry (3). One of the major disadvantages to using a prokaryotic
system is the lack of a nuclear membrane to compartmentalize the nucleus and
transcriptional machinery. Nevertheless, the fast growth rate (0.5 hours / duplication)
has made the utilization of prokaryotes for generating recombinant DNA and expressing
recombinant proteins a tremendous asset for scientists. E. coli was used to synthesize
human insulin through genetic engineering, and research utilizing E. coli remains active
to find alternative energy resources (4).
Saccharomyces cerevisiae. S. cerevisiae (baker‟s yeast, here forth referred to as
yeast) is the simplest model organism of the Eukarya domain. Yeast is widely used to
study basic eukaryotic cell biology and genetics, and the results obtained from these
studies impact our understanding of cellular functions higher eukaryotes. The ease of
2

genetic manipulation of yeast and its genetic complexity allows scientists to analyze
gene function (5). Yeast has been utilized to dissect an array of cellular functions
ranging from replication, transcription, cell cycle regulation and mRNA splicing, to more
complex processes such as cell signaling pathways, homologous recombination and Gprotein coupled receptors (6). Yeast has a fairly simplified genetic makeup (~4000
genes) for eukaryotic organisms with rare horizontal transfer gain of genes or gene
duplications (7).
Caenorhabditis elegans. C. elegans is a small, free-living soil nematode (round
worm) that has been used as the simplest multi-cellular eukaryotic organism. C. elegans
has organ systems, complex sensory systems and shows coordinated behavior, thus
making it a unique, yet simple animal to study at the embryological, neurobiological and
cellular levels. C. elegans can be grown and genetically manipulated with the speed and
ease of a micro-organism, making it a perfect organism to for genetic studies and
genomic manipulation (8). Furthermore, C. elegans is transparent, which allows for
visualization using a dissecting microscope to monitor cell movement. C. elegans has
been at the forefront of small RNA research and their regulation of gene expression (9).
Initial discovery of the first microRNAs (miRNA) and their function as regulators of gene
expression was discovered in C. elegans. Moreover, double-stranded RNA-induced
gene silencing and the current understanding of the RNA interference (RNAi) machinery
were also first discovered in C. elegans (10). This discovery unveiled a new mechanism
for gene regulation that is conserved in higher eukaryotes. Gene-function studies in C.
elegans remain easiest for the simple model of delivering double stranded RNA through
microinjecting the worm or feeding the worm bacteria that expresses the dsRNA.
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Drosophila melanogaster. D. melanogaster, commonly known as the fruit fly, is one
of the most commonly used organisms for classical and molecular genetics research.
Use of Drosophila as a model organism is alluring for many reasons including its easyto-manipulate genetic system, relatively low cost and fast generation time, and
biological complexity comparable to mammals (11). Many genes in the Drosophila
genome have well conserved orthologues in mammals with highly conserved epigenetic
mechanisms. Drosophila has been utilized to extensively study segmentation of its
body plan and the control of homeotic genes in this segmentation (12). Embryology and
development and oocyte polarity is another field where Drosophila has been used
extensively to unravel the basic mechanisms behind these fundamental processes.
Drosophila is also extensively used to study epigenetic transcriptional control, insulator
functions, and chromatin modifications because of the ease of mapping of its polytene
chromosome. Drosophila has long been used to study classical genetics and possess
many unique genetic markers that are manifested in visible phenotypes that can be
seen with the naked eye or under low-powered dissecting microscopes (12). The
utilization of recessive balancer chromosomes along with genetic markers makes it
easy to select for progeny with the desired homozygous mutation.
Other non-mammalian organisms. Other NIH sponsored non-mammalian organisms
include organisms from the Archea domain. Retroviruses, which are not classified as
living organisms, are also sponsored organisms by NIH, as well as the parasites from
the plasmodium genus, which cause malaria. Lastly, Dictyostelium discoideum
(social amoeba) and Danio rerio (zebrafish) are the other non-mammalian model
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organisms utilized in modern research laboratories for various studies including
reproduction.
Mammalian Model Organisms
Mammalian model organisms cover the mammalia class of the Animal kingdom
and are heavily utilized in modern science to research and investigate human disease.
Human subjects are not used for research purposes because of the obvious risk to life,
except in highly regulated clinical trials. Therefore, animal models are employed in the
study of human disease and they are chosen because of their similarity to humans on
genetic, anatomical, and physiological basis (13). Experimental research of diseases is
done on animal models because of their unlimited supply, ease of manipulation, and
controlled settings. To obtain scientifically valid research, the conditions associated with
an experiment must be closely controlled through manipulating only one variable while
keeping all others constant. Scientists then monitor the consequences of changing the
variable and record the observations to test their hypotheses. Since most experiments
require an adequate number of subjects for testing, it is easier for scientists to use large
numbers of animals to conduct their research. Animal models are used to study the
genetic etiology of diseases, as well as diagnosis and treatments of such disease.
Rodents are the most widely used NIH-sponsored mammalian model organisms due to
their similar physiology to humans and high genomic homology; however some studies
can use primates for more accurate studies of human diseases. The two rodent models
most used in scientific research are the mouse (Mus musculus) and the rat (Rattus
norvegicus). For the purposes of this dissertation, we will focus on the mouse as a
mammalian model organism to decipher gene functions.
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Mus Musculus. The common house mouse is one of the most commonly used
animals to study genetic principles and human disease. Humans and mice diverged 75
million years ago, since then, their genomes have evolved and changed at a rate of
nearly one substitution for every two nucleotides and by deletion and insertion
mutations (14). Yet, ortholgous sequences can still be aligned to resemble the
divergence and conservation of essential genes. The mouse genome is 14% smaller
than the human genome in terms of euchromatic regions with 2.5Gb (19 autosomes, 1
XY chromosomes) compared to 2.9 Gb (22 autosomes, 1 XY chromosomes) (14). The
human genome has undergone expansion since the divergence of humans and mice
with an overall ratio of 0.91 mouse/human locus span (measured in relative size of
orthologous landmarks in the genome). The human gene catalogue predicts 27,049
transcripts aggregated into 22,808 distinct predicted genes, while the mouse gene
catalogue predicts 29,201 transcripts clustered in 22,011 distinct genes. Moreover, 80%
of mouse genes have a strict 1:1 orthologue in humans, and the remaining genes
belong to a gene family that has undergone expansion. This shows the high degree of
homology between human and mouse genomes and the ability to correlate human and
mouse gene functions. Since both genomes have been sequenced and comparative
analysis of both genomes is established, the biomedical studies of human genes can be
complemented by experimental manipulations of a corresponding mouse gene, allowing
fast and reliable functional understanding of gene functions. In respect to the mouse
genome, there are practical techniques for random mutagenesis along with hundreds of
spontaneous mutations occurring in mice. However, the most important aspect of
mouse biology is the ability to change the genome through transgenic, knockout and
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knock-in techniques, allowing precise manipulation of the mouse genome (15). Thus,
the utilization of mouse is unmatched as a model system for probing mammalian
biology and human disease.
Methods for Inducing Human Disease.
Despite similar genetic homology between humans and mice, replicating human
disease conditions in mouse is complex due to the heterogeneity and outbred nature of
human alleles compared to the inbred strains of mice. Many human congenital and
developmental diseases are manifested as a result of chromosomal deletions and
aberrations of alleles that can eliminate multiple genes within the region (16). Moreover,
human diseases can be modified through single nucleotide polymorphisms (SNPs) and
copy number variants (CNVs), affecting penetrance and responsiveness to treatments.
Such studies are hard to duplicate in murine systems compared to modern reverse
genetics approaches which have undertaken the majority of active research. These
reverse genetics studies rely on various methods to interfere with gene function to study
the phenotype and effect of this gene on homeostasis. Selection of proper interference
method can ultimately affect the expressivity of the phenotype and the correlation of the
model to human diseases; therefore, we will discuss some of the current methods used
in creating genetically-modified mice.
Large scale mutation screens. N-ethyl-N-nitrosourea (ENU) is an efficient mutagen
used in the spermatogonia stem cells of mice to induce an array of different point
mutations. The progeny mice can be identified based on alterations to the wild type
phenotype and expansion of certain line based on the desired phenotype. On average,
a mutation is predicted every 2.38 Mb of gene-encoding sequences and a functional
7

mutation is expected every 9.48 Mb, thus making mutagenesis dispersed and random
(17). Although this technique is advantageous in generating multiple variable mutant
progeny, there are disadvantages to this technique. First, it‟s difficult to establish the
main causative mutation of the phenotype and requires multiple complementation
crosses, and secondly, it‟s difficult to assess whether one gene mutation or two
synergistic gene mutations contribute to the phenotype. One of the most successful
ENU-generated and most utilized mouse models is the multiple intestinal neoplasia
APC (ApcMin) mouse model, which was the first mouse model to recapitulate the human
Familial Adenomatous Polyposis (FAP) disease (18). ApcMin mice are heterozygous for
a germ-line mutation in Apc, and loss of heterozygosity due to somatic mutations
renders the protein non-functional and activates the Wnt signaling pathway.
Other large scale mutations involve radiation induced (e.g. X-ray) chromosomal
breaks and rearrangements (19). The main drawback to this mutagenesis system is the
excessive gene translocations and deletions, and chromosomal rearrangements. On the
other hand, this may simulate some human diseases where loci deletions and
chromosome aberrations underlie the disease. IR-induced genomic instability is utilized
as a method to induce cancers in mice mutant for DNA repair genes or any other gene
to test the tumorogenic potential of the specific gene (20).
Transgenic mice. Transgenic mice are generated by injecting foreign genetic material
either directly into the fertilized egg through „pronuclear microinjection‟, or injecting the
foreign DNA into nucleus of embryonic stem cells which are eventually injected into the
blastocysts of a fertilized egg (21). The content of the foreign genetic material integrates
into the genome of the embryo where it can modify the organism. Transgenic mice
8

expressing the exogenous Maloney leukemia virus were the first transgenic mice
created (22). Transgenes have a powerful promoter (e.g. CMV) upstream of the coding
sequence to drive efficient transcription of the gene. However, advancements of genetic
engineering have made transgenic mice more useful in biomedical research. Tissuespecific expression of exogenous genes has become a more useful model system that
depends on cloning a tissue-specific gene promoter upstream of the exogenous gene
construct (23). More recently, cloning a tamoxifen response element in the promoter of
exogenous genes induces gene expression through intravenous injection of the
hormone tamoxifen (24). However, the main drawback to transgene technology is that
integration of the foreign DNA into the genome occurs at random, and the number of
copies integrated varies. Therefore, transgene technology cannot be used to manipulate
endogenous genes in a predetermined manner.
Knock-Out and Knock-In mice. When a single gene is predetermined to trigger a
specific disease, targeted mutagenesis of this gene is essential to elucidate molecular
data of the etiology of the disease. Targeting a predetermined gene utilizes a molecular
technique that is both cumbersome and inefficient: homologous recombination (HR)
(19). The desired mutation is created through in-vitro gene targeting of Embryonic stem
(ES) cells which are then microinjected into blastocysts and eventually a pseudopregnant female for embryo development. The mutations in ES cells will be propagated
through all tissue of the adult mouse after a series of crossings and selections based on
coat color. In general, targeting of desired gene can result in „Knock-out‟ of gene
resulting in loss of function in the null allele, gain of function through „Knock-in‟ of a
transgene, or point mutation through exchange of an exon with a mutant exon.
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Targeting vector or foreign DNA material typically carries characteristic sequences and
markers for selection, in addition to the mutation of interest. Homologous recombination
requires sequences that are similar to the target region of interest where strand
exchange can take place (25). The vector also contains a neomycin resistance gene
within the targeting vector to positively select for ES cells that have undergone
recombination. A Thymine Kinase (TK) gene is found at in the targeting vector just
outside the HR exchange region, whereby if a cell doesn‟t undergo proper HR, TK will
be expressed and the ES cell will die. Although expensive, HR-mediated gene targeting
has become the most effective way of studying genes and their role in diseases.
Conditional gene modifications. HR mediated gene targeting sprung a new approach
to targeting mutagenesis in mouse models. Since many genes are embryonic lethal if
deleted, and many genes become inactivated in adults, a system that removes gene
function at specific times or in adult organism became a more realistic rendition of
human diseases (25). Scientists started targeting their genes by adding a flanking
sequence termed „LoxP sites‟ in their targeting vectors, in addition to the original
sequence of interest. Cre recombinase is an enzyme that recognizes these LoxP sites
and floxes them (deletes the intervening DNA depending on their orientation), which
often leads to deletion of an exon within the target gene. This creates a conditional gene
knock-out phenotype that depends on the expression of the Cre recombinase enzyme.
To add specificity to the system, Cre recombinase transgenic mice can be crossbred
with knock-out mice to create mice with both features in their genome. Regulation of the
Cre recombinase gene can be done at the promoter by adding a tissue-specific
promoter that allows expression of Cre in a tissue specific lineage rather than whole
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genome, thus targeting mutagenesis to the specified tissue. Additionally, a tamoxifen
response element can be used in the Cre promoter, thus allowing floxing of the gene
upon injection of estrogen to the bloodstream of mice (24).
Mouse Models for Tumorogenesis.
There are many paradigms that underscore the translational efficacy of mouse
models in understanding human disease. Despite having a high degree of genetic
homology between both organisms, some studies that were carried out in mice don‟t
translate into humans (26). There are well over 1000 mutant strains of mice and the
majority replicates an inherited human genetic disease or a human disease phenotype.
It‟s important to note that few models replicate all symptoms associated with complex
human diseases. Diseases that are hard to replicate in mice, but may otherwise be
studied in primates, include cognitive and neurodegenerative disorders (27). However,
one of the greater successes of mouse models comes from studying tumorogenesis
and the role of genes in promoting cancers. Neoplasia, abnormal proliferation of cells, is
a hallmark biological process during the multistep development of neoplasm (tissue
mass or cancer) (28). Mouse models have given us tremendous clues into identifying
„Driver mutations‟, a genetic modification that provides an advantage to cells to facilitate
tumor formation and survival (29). Gradually, the neoplasia accumulates more
„passenger‟ mutations in other genes important for DNA repair, cell proliferation and
death, angiogenesis and invasion, leading to neoplasm and metastasis. Mouse models
have played a great role in understanding these processes and identifying critical gene
mutations to drive tumorogenesis. Thus we will review some of the important models.
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Breast cancer models. Breast cancer is one of the most diagnosed cancers in females
and one of the primary sources of cancer-related deaths in the world. Mammary tissue
in mammals undergo changes during pregnancy, lactation, and weaning of offspring,
and therefore constantly undergoing angiogenesis, cell proliferation, and eventually
senescence and apoptosis (30). Mammals share this phenomenon in all females, and
studies on mice can ascertain the molecular mechanisms of the disease condition in a
conserved manner. Transgenic mice that over-expressed the oncogene Myc in the
mammary epithelium formed tumors in that region (31). The same group later reported
on the synergistic roles of H-Ras and Myc in mammary tumors; these strains, in addition
to others (ErbB2, TGFα) are still used to test drugs in mice that have breast cancer (30,
32, 33). Later studies revealed that Brca1 (breast cancer 1, early onset) inactivation in
mouse mammary tissue leads to genomic instability and tumor formation. This gene
was then found to be mutated in a great percentage of women who have early onset
breast cancer, and became a marker for breast cancer (34). Subdermal injection of
foreign tissue, also known as Xenograft transplantation of tumors, is a mechanism to
study tumor invasion and metastasis in mice, which lead to a better understanding of
mutations that aide in angiogenesis, epithelial-mesenchymal transition, transplantation
in other organs, and other features of breast cancer metastasis (30). Mouse models
remain a useful tool for pharmaceutical companies and their active research to test new
therapies for breast cancer.
Colorectal cancer models. Colorectal cancer (CRC) is a heterogeneous disease that
can be caused by accumulating somatic mutations due to aging, environmental and
chemical exposure, or diet leading to sporadic CRC (35). CRC represents the third most
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frequently diagnosed form of cancer. Familial adenomatous polyposis (FAP) and
hereditary nonpolyposis colorectal cancer (HNPCC) are the most common types of
hereditary CRC. Patients predisposed to FAP typically carry a germline mutation for the
tumor suppressor gene adenomatous polyposis coli (APC) gene (36). Additionally,
various somatic mutations of APC occur in about 85% of all sporadic CRC, and the
majority of these mutations occur in the mutation cluster region (MCR) of the gene.
Several mouse models that study early events of CRC have been developed and can
be divided into three major pathways; the mismatch repair pathway, the non-Wnt
pathway, and the Wnt pathway (37). The mismatch repair pathway was linked to
HNPCC when mice deficient for DNA mismatch repair (MMR) proteins Mhl1, Msh2, and
Msh6 developed gastric, intestinal, and colorectal cancers (38). The non-Wnt pathway
mediated mouse models examine the role of transforming growth factor beta (TGF-β) in
CRC and inflammation-mediated carcinogenesis (37). Studies on mice with TGF-β
mutations showed a tumor suppressor role in early CRC and an enhancer of invasion
and metastasis in late CRC. The Wnt pathway mutant mouse models provided a link
between hereditary FAP and Apc mutations. The multiple intestinal neoplasia APC
(ApcMin) mouse model was the first mouse model to recapitulate the human FAP
disease and continues to be utilized as a model for synergistic activation of onco-genes
in tumor progression (39). CRC mouse models can be use to study carcinogenic
molecules and chemicals, chemotherapeutic agents, and the roles of everyday drugs
like NSAIDs in CRC prevention and treatment.
Models for other cancer hallmarks. There are other mouse models of human cancer
which can‟t be categorized into a specific organ or class. However, there are many
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models that describe other fundamental processes of cancer formation, progression, or
invasion, and these models cover a wide spectrum of genes. Hanahan and Weinberg
recently characterized the six biological hallmarks of cancer to be: „sustaining
proliferative signaling, evading growth suppressors, resisting cell death, enabling
replicative immortality, inducing angiogenesis, and activating invasion and metastasis‟
(28). Perhaps one gene above all else has been the centerfold of all cancer research,
the tumor suppressor protein p53. Deregulation of p53 activity is seen in approximately
70% of all cancers, and these are conserved estimates (40). Because of the complexity
of the p53 pathway, its interacting proteins, and its direct-induced genes, it‟s likely that
p53 contributes to all six fundamental hallmarks of cancer, hence the term‟ guardian
angel of the genome‟. Several p53 mutant mouse models exist to study the extensive
phenotypes caused by various mutations in p53. To mimic human mutations in p53
which are typically single nucleotide polymorphisms (SNP), recent work has shifted
towards recreating these SNPs in mouse models (41-43). These studies may contribute
to the molecular mechanisms of increased tumor susceptibility of p53 polymorphisms.
Future studies may also look into the effect of polymorphism of p53 effectors and
response genes in tumor susceptibility and responsiveness to therapeutic agents. ATM,
p21, and MDM2 are p53 pathway genes that have been reported to have polymorphism
that contributes to cancer susceptibility, while polymorphisms in the promoters of p53
target genes (BAX, BCL2, PIG3) have been reported to affect tumor susceptibility (43).
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Chapter II
Eukaryotic Transcription Regulation, and The Forkhead Box Family of Proteins
Introduction to Eukaryotic Transcription Regulation
Transcription is the fundamental process of the cell by which genetic information
stored in DNA is activated through the synthesis of a complementary messenger RNA.
Transcription is a highly regulated process in Eukaryotic cells at hierarchical levels that
include pre-initiation, elongation, termination and epigenetic chromatin structure.
Eukaryotic RNA Polymerase II, which is responsible for transcription of protein-coding
genes, is composed of multiple subunits but lacks the capacity to initiate transcription in
a purified form (44). Instead, the RNA polymerase requires the activity of general
transcription factors to recognize a DNA sequence and initiate transcription of all genes;
these „basal‟ transcription factors are TFIIB, D, E, F, and H (45). Schaffner and
Chambon identified gene-specific „enhancer‟ elements that bind „activator proteins‟ to
allow transcription of specific genes (46). Kornberg purified the „mediator‟ complex that
links the regulatory elements of specific gene expression with general transcription
factors and RNA polymerase. This introduced the concept of cis- and trans-regulatory
elements that control the activation of specific-gene transcription. Transcription factors,
known as trans-regulatory elements, can bind to specific sequences in upstream
regulatory regions and gene promoters, known as cis-regulatory elements to selectively
activate gene expression in a specific manner.
Transcription Factors
Eukaryotic transcription regulation is mediated through transcription factors
(trans-regulatory elements) that can act as either „Activators‟ or „Repressors‟ of
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transcription. The primary domains of all transcription factors (TFs) include a DNA
binding domain and trans-activation domain; however, many TFs include an additional
ligand-binding domain (47). The majority of transcription factors possess DNA-binding
domains that can recognize specific DNA sequences formed at the major grooves (48).
DNA-binding domains can be generally broken down to one of five major classes: Basic
domains (helix-loop-helix), helix-turn-helix (e.g. Homeodomains, winged/forkhead), Zinc
finger domains, β-scaffold domains (e.g. MADs box), or steroid hormone receptor (49).
These domains are amphipathic amino acids rich motifs with the DNA binding surface
rich in aromatic amino acids. Transcription factors can homo- or hetero-dimerize and
recruit the basal transcriptional machinery to initiate transcription; hetero-dimerization
provides an additional layer of diversity in transcription regulation. While the majority of
transcription factors activate transcription, some function as repressor protein by binding
to DNA sequences that overlap activator-binding sites or by binding to sequences that
overlap a transcription start site.
Transcription factors have a „Transactivation domain‟ (TAD) that links DNA
recognition with recruitment of the transcriptional machinery. TADs are enriched with
conserved acidic and hydrophobic amino-acids that are critical for transactivation of
transcription (50). Some transcription factors have a nine-amino-acid transactivation
domain, 9aa TAD (51). TAD is a common motif to a large number of yeast (Gcn5, Gal4,
Oaf1, and Pho4) and animal transcription factors including VP16, p53, NF-IL6, NFAT1,
and NF-κB. The TAD domain of these transcription factors interacts directly with the
general transcriptional cofactor TAF9 (TAFII31), a component of TFIID and the basal
transcriptional machinery. The third domain of most transcription factors is a ligand-
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binding domain or a sensory domain, which initiates transactivation of the TF, as in the
case of Estrogen Receptor (ER) (52).
Regulation of Transcription Factors
Translation and nuclear localization
Activation of TFs is regulated at different levels in the cell to assure timely and
tissue specific gene transcription. TFs, just like all functional genes, are transcribed in
the nucleus and exported to the cytoplasm for translation into a functional protein. TFs
are active in the nucleus and possess a nuclear localization signal (NLS), a sequence of
positively charged amino acids exposed on the surface of the protein (53). NLS is then
recognized by the Karyopherin family of proteins (include Importin and Transportin
proteins) that transport the transcription factor through the nuclear pore into the nucleus
in an ATP-dependent process (54). However, regulatory proteins can bind to
transcription factors and sequester them in the cytoplasm by masking the NLS binding
site, thus rendering the protein unable to translocate to the nucleus to activate
transcription. Inhibitor of κB (IκB) binds and sequesters the transcription factor NF-κB in
the cytoplasm, thus regulating it transcriptional activation function in a non-specific
manner (55). Moreover, IκB achieves NF-κB sequestering in the cytoplasm by masking
its NLS signal and preventing its translocation to the nucleus (56). Other TFs are
sequestered by interactions with specific regulatory proteins. MDM2 is an E3 ubiquitin
ligase protein and a negative regulator of the tumor suppressor TF p53; MDM2 binds to
p53 in the cytoplasm and induces proteasome-mediated degradation of p53 (57). Betacatenin, a component of the Wnt signaling pathway, is another transcription factor that
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is sequestered in the cytoplasm by binding to the transmembrane protein E-cadherin, or
binding to APC/Axin/GSK-3β complex to mediate protesaomal degradation (58).
Activation signals
Activation of TFs is a complex process that depends on the inherent domains of
TFs (Ligand binding domain) and other regulatory proteins. In the case of steroid
receptors (e.g. Estrogen, Glucocorticoids), binding of the steroid leads to dissociation of
the cytoplasmic co-repressors (Src for ER, HSP70/90 for GR) and translocation to the
nucleus, where the receptor dimerizes and binds to its response element and recruits
additional co-activator proteins (59, 60). However, a more complex chain of regulatory
proteins exists for the tumor suppressor protein p53. DNA damage triggers multiple
kinases to phosphorylate p53 at Ser15 and Ser37 by ATM/ATR and DNA-PK (61). This
phosphorylation weakens the affinity of MDM2 interactions with p53, thus promoting
both the accumulation and activation of p53. Additionally, the checkpoint kinases Chk1
and Chk2 can phosphorylate p53 at Ser20, enhancing its tetramerization, stability and
activity (62). This tetramerization of p53 occurs in the nucleus and masks the nuclear
export signal (NES) to maintain p53 transactivation (63). Acetylation of p53 is a second
modification mediated by p300 and CBP acetyltransferases, which enhances p53 DNA
binding domain affinity to bind its response element (64). Another level of p53 regulation
occurs through ARF, which binds to MDM2 and promotes its rapid degradation, thus
stabilizing p53 and maintaining its transcriptional activity (65). In many instances, the
transcription factor is found inside the nucleus, but is bound to a negative regulator. The
Retinoblastoma protein (pRB) is a tumor suppressor protein that negatively regulates
cell-cycle progression by binding to the E2F transcription factor and masking its
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transactivation domain, thus inhibiting its transcriptional activation of genes that encode
DNA replication proteins (CDC6, TK) (66). pRB is typically hypo-phosphorylated and
bound to E2F; however, its interaction with E2F is reduced upon phosphorylation by
checkpoint proteins Cyclin D/CDK4/6 and Cyclin E/ CDK2 to promote DNA replication.
Transcriptional regulatory complexes
The TAD domain of TFs allows for competitive interactions with proteins or
protein complexes that can either activate or repress transcription. These protein
complexes recruit chromatin remodeling proteins that modify the DNA to allow for DNAbinding domains of TFs to recognize their cis-regulatory sequences and promote genespecific transcription. TCF is a transcription factor that recognizes its cognate Lef-1 site
on target genes; however, TCF is typically bound to Groucho, a protein that interacts
with HDAC1 to repress transcription (67). Once the Wnt signaling pathway component
β-catenin translocates to the nucleus, it displaces Groucho from TCF and interacts
directly with TCF, allowing for gene transcription. The oncoprotein c-Myc is a
transcription factor that binds E-boxes of DNA to activate transcription of specific target
genes (68). C-Myc heterodimerizes with MAX, another transcription factor to enhance
the specificity of DNA interaction of c-Myc. Upon binding to the E-Box, c-Myc interacts
with histone acetyltransferase (HAT) enzymes to modify the chromatin and enhance
transcription. However, Mad family of proteins compete for binding with Max and C-myc
and can thus form heterodimers that can recognize the E-Box sequences (69). Madcontaining dimers antagonize c-Myc dimers by interacting with the mSin3a protein,
which in turn recruits histone deacetylase (HDAC) enzymes to compact chromatin and
reduce transcription.
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Transcription Factors and Signaling Pathways
Many transcription factors belong to conserved families of proteins that function
in a signaling cascade to regulate gene expression. These signaling pathways are
involved in multiple cellular and developmental processes and mutations to any
component of these conserved pathways lead to an array of developmental disorders
and cancers. Signaling pathways are used in multicellular organisms to communicate
between cells and utilize ligands, growth factors, and receptors to initiate these
changes. The mitogen-activated protein kinase/Erk (MAPK/Erk) signaling pathway is
involved in cellular growth and differentiation, and is activated by a wide variety of
receptors including the epidermal-growth factor receptor (EGFR) (70). EGFR is a cellsurface receptor that belongs to the Erb family of tyrosine kinase receptors; it‟s
activated by binding of the EGF ligand and the transforming growth factor α (TGFα) as
they both function in cell proliferation and differentiation (71). Activation of EGFR leads
to sequential activation of an adaptor (GRB2), linking the receptor to a guanine
nucleotide exchange factor (SOS) and transducing the signal to small GTP binding
proteins (Ras), which in turn activates the core unit of the cascade composed of a
MAPKKK (Raf), a MAPKK (MEK1/2), and MAPK (Erk). These proteins can then signal
terminal transcription factors like Activating Protein 1 complex (c-Fos and c-Jun), c-Myc,
and cAMP reponse element binding (CREB) to activate gene transcription (72).
The NF-κB transcription factor is an important regulator of cellular response to
multiple stimuli, but most importantly those of cytokines and viral antigens, to mount an
immune response and protect the organism (73). Amongst the transcriptional targets of
NF-κB is the promoter of the kappa light chain, an essential component of antibodies
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responsible for creating the diversity in the immune response. NF-κB activation is
receptor mediated and involves different families including Receptor activator of nuclear
factor kappa B (RNAK), a member of TNFR family, Toll-Like Receptors (TLR), and
Interleukin Receptors (74). Ligand binding to these receptors activates one of two
kinases, MEKK3 (MAPK/Erk Kinase Kinase 3) and NIK (NF-κB Inducing Kinase). Both
kinases lead to activation of IKK to phosphorylate IκBα (Inhibitor of κB) and its
degradation, thus exposing the NLS signal of NF-κB to translocate to the nucleus (75).
Interleukin receptors can mediate another signaling pathway, the JAK/STAT pathway.
Binding of Interleukins to their receptors leads to auto-phosphorylation of the JAK family
adapter protein, which then proceeds to phosphorylate its target STAT family of proteins
(76). This leads to dimerization of STAT proteins and translocation to the nucleus to
activate transcription.
The Notch and Wnt signaling pathways are essential to eukaryotic embryonic
development and tissue specificity. Notch is a transmembrane protein with an extracellular and intra-cellular domain. There are four different Notch family receptors
(Notch1-4) that can interact on the cell surface with five ligands (belong to Jagged and
Delta families of receptors) (77). The Notch pathway regulates cell fate determination of
neighboring cells through lateral inhibition, depending on their ability to express either
the receptors or the ligands. Upon ligand binding to the extracellular domain of Notch
receptors, two different proteases get activated: the ADAM proteinase family to cleave
the extracellular domain, and the γ-secretase complex to cleave the intracellular
domain. The intracellular domain then translocate to the nucleus where it interacts with
multiple proteins to activate transcription (78). Similarly to the Notch pathway, the Wnt
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signaling pathway is activated by binding of the Wnt ligand to the Frizzled receptor,
which forms a complex with LRP and Dishevelled. Binding of the Wnt ligand activates
the protein Dishevelled to bind to the “destruction complex” composed of Axin, APC,
GSK-3β and Beta-catenin. Dishevelled then phosphorylates Axin thus weakening the
affinity of the destruction complex and GSK-3β ability to phosphorylate β-catenin and
target it for destruction (67). Β-catenin then enters the nucleus and activate transcription
by binding to its Tcf/Lef1 sites.
Superclass Helix-turn-Helix
The Superclass Helix-Turn-Helix transcription factors share a unique DNA
recognition domain. Family members of this Superclass include the Homeobox domain
family (including Paired box), the Fork head / Winged helix family, the Heat Shock
Factors, and the transcriptional enhancer factor (TEA) family (49). Perhaps the
Homeotic box (HOX) family and the Forkhead Box (FOX)/Winged helix proteins family
are the best known members of this superclass. The FOX family will be discussed in
great details later in this chapter. Hox genes encode transcription factors defined by the
DNA-binding domain termed the homeodomain that function independent of conserved
signaling pathways (79). Hox genes are present in all animals and the homologues are
highly conserved. Hox genes in vertebrates are located contiguously in clusters with the
number of these clusters varying according to anatomic complexity. There are 4 Hox
clusters in mammals (HOXA, B, C, and D) and 39 Hox genes have been identified in
humans. Hox genes have been well studied in Drosophila, where they have been
shown to be involved in normal temporo-spatial limb and organ development along the
anterior-posterior (A-P) axis. There are three basic mechanisms utilized by Hox cluster
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to regulate normal tissue development in vertebrates: spatial collinearity, posterior
prevalence, and temporal collinearity (80). Spatial collinearity correlates the position of a
Hox gene in the cluster with its tissue expression along the A-P axis. Normally, 3′ genes
within the cluster are expressed in anterior tissues and 5′ genes in posterior tissues.
Posterior prevalence postulates that Hox genes which are positioned more 5′ in the
cluster will have a dominant phenotype to those more 3′. This is due to transcription of
microRNA embedded along with HOX gene in the cluster; miRNA can then silence
more upstream HOX genes. Temporal collinearity is similar to spatial collinearity but
correlates temporal tissue order of expression of Hox gene with the cluster.
HOX proteins have been shown to effect essential cell processes like cell
migration, cell cycle control, apoptosis, cell adhesion, and development. HOX proteins
function at the „high level executive‟ stage during development, which denotes targeting
of „executive genes‟ that encode transcription factors, cell-cell signaling, or morphogens
(80). Decapentaplegic is an executive gene regulated by the Drosophila HOX gene
Ultrabithorax and Abdominal-A, and it expression triggers cell shape changes in the gut
that are required for normal visceral morphology. These two HOX proteins also regulate
distal-less expression, a gene involved in limb formation. Meanwhile, Deformed is
another HOX gene that regulates reaper expression, which in turn activates apoptosis
during maintenance of the boundary of maxillary and mandibular segments of the head.
HOX proteins are less well studied in higher mammalian development, but studies have
shown a role in cell-cycle regulation and cancer. Hoxa10 appears to be activated during
differentiation of mouse cultured myelomonocytic cells into monocytes followed by
growth arrest; this was attributed to the induction of cell-cycle arrest protein p21 (81).
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The Forkhead Box
The forkhead family is a large family of transcription regulators that share a
structurally related DNA binding domain: the forkhead (82, 83). Originally, the fork head
gene (fkh) was discovered as a mutation in Drosophila melanogaster which presented
with an ectopic/displaced head in larvae and a spiked head phenotype in adult flies.
Expression of the fkh gene was determined to be in the terminal domains of the D.
melanogaster embryo which correlate to the anterior head and posterior tail of an adult
fly (84). Protein sequence analysis indicated the lack of a homeo domain in the fkh
protein, and the sequence showed no similarity to any known protein family. The closest
discovered homologous protein factor that had been identified to play a role in head/tail
development was the spalt (sal) gene of the „region-specific homeotic genes‟ family
(84). However, the fkh protein was not structurally related to the sal protein. Meanwhile,
Lai and his group were able to clone the cDNA encoding Hepatocyte Nuclear Factor 3α
(HNF3α) in rat liver (85). Sequence analysis of HNF3α revealed no similarity to the
homeo domain protein HNF-1 or the Leucine-zipper protein C/EBP, which play a role as
liver nuclear transcription factors. Lai and colleagues limited the DNA-binding region to
amino acids 124-288 of the protein and predicted short α-helices based on the
abundance of proline and glycine residues (85). Detlef Weigle and Herbert Jackle
compared the Drosophila fkh protein with the mammalian HNF3α protein. In comparing
the DNA-binding domains of both proteins, they noticed 86% identity and 92 %
conservation in a 110 amino acids span of Drosophila and mammalian Fox proteins
which contained the DNA binding motif (86). HNF3α was later renamed FOXA1 and the
other HNF3β and HNF3γ proteins identified in the study were assigned to the FOXA
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subfamily as FOXA2 and FOXA3 respectively. Subsequent crystallography of the
FOXA1 protein revealed the structure of Forkhead proteins and its interaction domains.
FOX crystal structure and phylogeny
Clark et al first resolved the structure of HNF3γ (FOXA3) interacting with a 13
nucleotide region of the transthyretin (TTR) promoter previously used to identify HNF3
family of proteins. Crystal structure of the forkhead domain of FOXA3 shows the
presence of three α-helices (H1, H2, and H3) at the N-terminus of the protein. There are
also three β-strands (S1, S2, and S3) located towards the C-terminus of the FOXA3
protein (87). A polypeptide sequence connects S2 and S3 to form the first loop (W1),
and another polypeptide sequence is found after S3 to form the second loop (W2). S1 is
found between helices 1 & 2 and interacts with S2 and S3 to form an anti-parallel Bsheet. Different from homeo domains, The N-terminal region of Forkhead proteins
interacts with C-terminal region via S1 to form a hydrophobic core. A closer look at the
interaction of a FOXA3 monomer with TTR promoter shows interactions of H1 and H2‟s
N-termini with the phosphate backbone of DNA likely in the minor grooves. H3 interacts
with the major groove of DNA, and both wings border this interaction. The W1 and W2
loops flanking the H3 interacting with the major grove yields a butterfly shaped
interaction, which has given the term “winged helix” to Forkhead proteins. Side-chains
of the helices and wings interact with DNA phosphate and ribose groups; this includes
multiple W2 arginine residues found to interact with the minor and major grooves of
DNA at specific nucleotide positions. Other residues were shown to interact specifically
with sense or anti-sense nucleotides of the DNA fragment (87).
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After the discovery and classification of the HNF3 proteins as the first members
of forkhead/winged helix proteins, many scientists began to discover other proteins
containing the same domain among various chordates (88). FOX (Forkhead Box) was
adapted as the nomenclature for such proteins, and phylogenetic analysis further
classified FOX proteins into 15 subclasses (FoxA through FoxS) depending on
conservation of the forkhead domain. Arabic numerals designate members of a
subclass of FOX proteins which depends on protein sequence (88). Homeobox genes
(Hox) are a class of important transcription factors involved in development.
Functionally related Hox, Parahox, and Nkx genes are clustered together in
chromosomal regions (89, 90). However, no such clustering occurs for the Fox family of
genes except for a few gene clusters. A cluster of FoxL1, FoxC, FoxF and FoxQ1 was
identified in the chordate amphioxus. In humans, two different clusters were identified
on chromosomes 16q24.3 and 6p25. On chromosome 16q24.3, the FOXL1, FOXC1
and FOXF2 genes were found within a 70 kb span. At chromosome 6p25, the FOXC2,
FOXF1 and FOXQ1 genes were found within a 325 kb span (90).
FOX proteins and development
FOX proteins differ from related Superclass helix-turn-helix HOX genes in their
function as terminal transcriptional effectors rather than high-level executive proteins.
FOX Proteins can function individually and redundantly as monomers or in an
overlapping manner. FoxA1 and FoxA2 cooperate during endoderm differentiation into
lung epithelium and during liver morphogenesis and hepatic specification (83, 91, 92).
Moreover, FOXF1 and FOXF2 exhibit non-allelic and non-complementation functional
overlap as homozygous Foxf2 mutants and Foxf1/Foxf2 heterozygotes displayed gut
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and intestinal development problems including megacolon, colorectal muscle
hypoplasia and agangliosis (91). Mutations in FOXO3a and FOXL2 result in premature
ovarian failure (93). Foxc1 and Foxc2 have interactive and essential roles in cardiac
morphogenesis because compound heterozygotes exhibit similar cardiac or renal
phenotypes to single null mutants (94). Foxd1 and Foxd2 also exhibit an additive and
synergistic role in renal development, and Foxc1 and Foxc2 also appear to affect renal
development especially migration of renal cells (95). Foxc1, Foxc2, and Foxl2 are
expressed in the neural-tube derived ocular tissue and mutations in these genes lead to
abnormalities in ocular development. Many FOX genes (Foxd3, Foxc1, Foxc2, Foxl2)
are expressed in the neural crest and mutations to these genes result in cell-migration
defects and organ defectsFoxb1b deletion results in neural tube closure defects,
reduced posterior body axis and embryonic lethality, while Foxh1 mutations affects leftright axis specifications (95). FOXE1 is involved in cranio-pharyngeal development and
mutations lead to thyroid agenesis and other phenotypes. Foxi1 is responsible for innerear development, especially the vestibulum and cochlea (96). Foxn1 and Foxp3
mutations exhibit severe immune-system defects, as Foxn1 is highly expressed in skin
and thymus tissue and maintains balance between proliferation and differentiation (95).
FOX proteins and transcription
Forkhead box proteins can bind DNA as monomers and independently regulate
transcription by working as activators, repressors, or can have a dual function. FOXD2
over expression was shown to bind the RIα1b promoter and increase its sensitivity to
cAMP, thus inducing RIα mRNA and protein level, which is involved in T-cell activation
(97). Additionally, the FoxD2 avian homologue (CWH-2) was shown to act as
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transcriptional repressor by binding to Qin/BF-1 promoter sites of genes involved in
brain development and oncogenesis (98). In some cases, splice variants of the same
gene can function as activators or repressors (99). The Foxm1 (Human homologue
TRIDENT/FKHL16) protein is a winged helix protein specifically expressed in rapidly
dividing cells and is involved in controlling mitosis and promoting S phase and G2/M
phase progression (99, 100). The 396BP region upstream of the Foxm1 gene start
codon is responsible for modulating and transducing growth factor stimuli to effect
expression of Foxm1 (100). FOXM1a is a splice variant of the FOXM1 gene which binds
the FOXM1 consensus sequence but does not trans-activate genes. However, FOXM1b
and FOXM1c are involved in the activation of many genes (c-myc, c-fos, Cyclin-B,
Cdc25B) involved in cell-cycle regulation, genomic stability, and tumorogenesis (99).
Additional diversity in FOX proteins regulation of transcription can be achieved by
interacting with signal transduction protein complexes. The forkhead activin signal
transducer-1 (FAST-1) or FOXH1 is a forkhead protein that interacts with human Smad2
and Smad4 to activate the Activin Response Element (ARE) (101). The activation of the
ARE by the complex is dependent on the presence of a TGF-β stimulating peptide,
which suggests the FOXH1-Smad complex functions as a signal transduction cascade
in the TGF-β pathway. Seoane, et al presented more evidence supporting a role for
FOX proteins in signal transduction when they showed a role for FOXO family of
proteins in regulating p21Cip1 through a TGF-β signaling pathway. FOXO proteins were
shown to form a complex with Smad2, 3, and 4 and positively activate p21 Cip1 and relief
its c-myc repression (102). Moreover, FOXG1 was shown to be a negative regulator of
the Smad-FOXO induction of p21Cip1 in neuroepithelial cells by interacting with Smad-
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FOXO complex. FOXG1‟s role in progenitor neuro-epithelial cell development was
previously studied, and it was shown to be a transcriptional repressor to differentiation
signal stimulation (103). Foxg1 plays a similar role in the regulation of Foxh1 during lung
development. Analysis of glioblastoma multiforme tumor samples and cell lines showed
an increased expression of FOXG1, which suggests a role for the silencing of TGF-β
mediated p21Cip1 induction (102). Other FOX transcription factors function as terminal
effectors for other conserved signaling pathways including Hedgehog, Insulin/IGF, Wnt
signaling pathway, and MAPK/Erk (93).
FOXN Subfamily
The N subfamily of FOX proteins was first discovered when Li and colleagues
identified the human T-cell leukemia virus enhancing factor (HTLF) as protein that
bound the human T-cell leukemia virus long terminal repeat (HTLV-1 LTR) at the -117
to -155 region (104). The DNA binding domain of the HTLF resembled the forkhead
protein which was newly characterized, and the HTLF was later identified as the second
member of the N-Subfamily (FOXN2). The FOXN subfamily received more significance
when Nehls and colleagues were able to clone the nude locus of mouse chromosome
11 (105). Characterization of the protein encoded by this region yielded a 648 amino
acid protein with a DNA binding domain that resembled the forkhead domain (105).
Interestingly, the newly discovered protein showed a 56% identity to the human T-cell
leukemia virus enhancing factor (HTLF), which was earlier identified by Li and
colleagues. The protein, later assigned FOXN1, was found to be mutated in nude mice
which have rudimentary thymus and lack a T-cell induced immune defense (106).
Down-regulation of hair keratins, abnormal morphogenesis of hair follicles, and failure to
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develop a thymus from the ectoderm are characteristics of nude mice (106). FOXN1
expression was later shown to be regulated by Wnt4 of the Wnt pathway which utilizes
the PI3K-Akt to phosphorylate FOXN1 in thymic epithelial cells (107). Pati and
colleagues isolated a high-copy suppressor of the S. cerevisiae MEC1 G2-M checkpoint
mutants that conferred increased survival of G2-M checkpoint mutants (108). The
protein encoded by the cDNA was called Checkpoint suppressor 1, and characterization
of the full length protein showed homology to the forkhead/winged helix DNA binding
proteins (108). Moreover, CHES1 sequence showed high homology to the human T-cell
leukemia virus enhancing factor (HTLF) with 51% identity and 69% conserved residues.
Identification of members of the N subfamily continued when Gouge and colleagues
used the forkhead domain of Foxg1 to screen a mouse‟ eye cDNA for new proteins
utilizing low-stringency hybridization (109). They identified FoxN4, a 523 amino acid
polypeptide where sequence analysis predicted an activation domain and a DNA
binding domain. The later domain showed high similarity to HTLF/FOXN1, and in-situ
hybridization analysis showed specific expression in neural tissue and exclusively in the
retina after embryonic day E13.5 (109). Most recently, Katoh was able to clone and
identify FOXN5 and FOXN6 who share a 69 amino acid FN56 domain in addition to the
forkhead domain (110, 111). In a study on FoxN expression in Xenopous laevis, FoxN5
mRNA was shown to be maternally expressed, and FoxN5 transcripts are degraded
during gastrulation and completely eliminated by neurlation (stage 15) (112).
Interestingly, FOXN6 mRNA was shown to be expressed in breast cancer cell lines and
primary breast cancers, and FOXN5 was associated with the human B-cell
CLL/lymphoma 9-like (BCL9L) gene. A nuclear complex, which consists of BCL9L,
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human T-cell leukemia virus enhancing factor, and beta-catenin, is shown to activate
Wnt signaling pathway dependent expression of many genes including the oncogene
Myc (113).
FOXN3 (Checkpoint Suppressor 1)
FOXN3 (also known as Checkpoint suppressor 1, FoxN3) belongs to the N
subfamily of forkhead box transcription factors. Initial discovery and characterization of
the protein was done by Pati and colleagues when they screened checkpoint-mutant
Saccharomyces cerevisiae transfected with human cDNA for rescue of phenotype
(108). Tx23, a human cDNA isolated from U118 glioblastoma cell line, was isolated as a
high-copy suppressor of the S. cerevisiae MEC1 G2-M checkpoint mutants. The protein
expressed by the tx23 cDNA, Checkpoint Suppressor 1 (CHES1), conferred increased
survival of mec1-1 mutants to methyl methanesulfonate (MMS), UV radiation, and
ionizing radiation which are DNA damage agents. Meanwhile, full length cDNA of the
CHES1 protein restored G2-M checkpoint function in rad9 and rad24 mutants to
wildtype levels. Analysis of the CHES1 protein encoded by the full length cDNA showed
a novel protein that shares a common region with the forkhead/winged-helix family. The
protein showed greatest homology to the human T-cell leukemia virus enhancing factor
(HTLF). Interestingly, the 200 amino acids at the carboxy terminus of the CHES1
protein isolated were sufficient to restore the mec1-1 G2 checkpoint mutants in S.
cerevisiae (108). However, the carboxy terminal did not encode for the forkhead DNA
binding region.
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The C-terminal portion of the human FOXN3 protein was found to interact with
Sin3, a component of the Sin3/Rpd3 histone deacetylase complex (HDAC) in budding
yeast (114). The Sin3/Rpd3 HDAC complex is targeted to specific promoter regions via
Sin3 interactions with site-specific DNA-binding proteins (115). CHES1/FOXN3 appears
to inhibit the activity of Sin3/Rpd3 as deletion of Sin3 in Rad9 deficient S. cerevisiae
conferred resistance to UV damage similar to the results seen upon CHES1 introduction
to Rad9 deficient S. cerevisiae (114). Other studies showed the C-terminus of FOXN3
represses transcription when targeted to a reporter promoter in cell lines derived from
tumor tissues, which is consistent with its interaction with the Sin3/Rpd3-HDAC complex
(116). Moreover, CHES1 interacts with the C-terminus region of the Ski-interacting
protein, SKIP; this interaction varies from the well conserved SNW protein-binding
domain of SKIP (116). SKIP is a well-conserved nuclear regulatory protein involved in
pre-initiation of transcription, splicing and polyadenylation of RNA (116, 117). In addition
to the Ski protein, SNW/SKIP interacts with many proteins including the tumor
suppressor protein Retinoblastoma and receptor-regulated Smad2 & Smad3 proteins,
which are TGF-β modulators (117). SKIP functions to recruit either activation or
repression complexes to mediate multiple signaling pathways that are involved in cell
proliferation and differentiation (118). CHES1‟s transcriptional repression of the GAL4
reporter promoter can be correlated to CHES1‟s interaction with SKIP, which has been
shown to recruit many repression complexes, including mSin3a, HDAC1, HDAC2, and
NcoR/SMRT (116, 119). Case reports on human patients with deletions of the
chromosomal region containing FOXN3 have shown phenotypes that include,
dysmorphic features, delayed development, absent speech, auditory neuropathy,
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craniofacial defects, dental anomalies, microcephaly (abnormally small head), skeletal
defects, and hypotonia (120, 121).
The human FOXN3/CHES1 has been mapped to 14q32.11 while the mouse
Foxn3 was mapped to chromosome 12, region E (108). The human FOXN3 gene
encodes a 490 amino acids protein with a predicted molecular weight of 54 kDa, while
the mouse Foxn3 encodes a 457 amino acids protein with a predicted molecular weight
of 50 kDa. Human FOXN3 has a splicing variant which is encoded by exon VI and adds
an additional 66 bp (22 amino acids) to the gene transcript. Also, There is a variable
leader exon which is used equally in both splice variants (112). In-situ hybridization
analysis using FoxN3 probes in Xenopus laevis shows a persisitent expression in the
eye, the branchial arches and the vagal ganglion.
The role of FoxN3 in mammalian development is not known due to the lack of
data relating to animal models that are defective in FoxN3 expression. However, recent
studies have shown the involvement of FoxN3 in craniofacial and eye development in
Xenopus laevis (122). X. laevis larvae injected with FoxN3 antisense morpho-olino (MO)
were shown to have reduced eye size, reduction and false positioning of craniofacial
cartilages, increased apoptosis in the brain, and reduced food intake. Cranial nerves,
including hypoglossal and branches of the trigeminal nerve, were either lost or severely
deformed especially nerve branches that innervate the lower jaw. The severity of the
phenotype progressed with the developmental stage of the X. laevis larvae beginning at
stage 41 onward and ending at stage 50 when reduced food intake ultimately lead to
death. The severity of phenotype was also antisense MO dose dependent with greater
and a more severe phenotype being produced with complete reduction of FoxN3 (122).
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This may suggest that nullyzygoisty for FoxN3 in higher mammals would be lethal while
heterozygosity may demonstrate phenotype.
Foxn3 mouse model
In an effort to understand the role FoxN3 in mammalian development, we have
developed a mutant mouse model for the Foxn3 gene. Foxn3 deficient mice were
generated using the Baygenomics gene trap embryonic stem cell resource. The
Baygenomics insertional mutagenesis strategy involves the use of a gene-trap cassette
consisting of a splice-acceptor-βgeo cassette (β-galactosidase-neomycin fusion gene)
and characterized using 5‟ RACE (Figure 1). We obtained one of the ES cell clones that
had been characterized to have a gene trap insertion within the Foxn3 gene for analysis
of the gene trap insertion site. Using multiple intronic forward primers and a gene-trap
specific reverse primer for PCR amplifications and sequencing, we determined the
gene-trap insertion site to be in intron 3 (Figure 2). Foxn3-targeted ES cells were used
for blastocyst injections using the microinjection services at the University of
Massachusetts Medical School, Worcester. Germ line founder mice were generated
and the colonies were expanded for the analysis of the mutant offspring. The working
model for the Baygenomics gene traps encompasses the splicing of the 5‟ splice site of
Foxn3‟s exon 3 (encoding the first 218 amino acids) into the 3‟ splice site in the gene
trap (123). This allows for the in-frame fusion of the first three exons of Foxn3 to the Bgalacotsidase neomycin sequence and the expression of this fusion protein. The
expression of this fusion protein is mandated for the blastocysts to survive neomycin
selection. Upon efficient splicing of the Foxn3 gene into the gene trap, the remainder
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exons will not be translated and thus the wild type protein will be haplo-insufficient in
heterozygous progeny and completely lost in nullisomic progeny.

En2

Foxn3

SA

β-Geo

Exon 3

SV40pA

Gene trap

Exon 4

En2: Engrailed 2 intron sequence
β-Geo: β-gal-neomycin fusion gene

SA: Splice Acceptor site
SV40pA: SV40 poly A

Figure 1. Schematic representation of the Baygenomics gene trap integrated into intron 3 of Foxn3 gene.
The gene trap cassette contains an Engrailed 2 intronic sequence followed by a splice acceptor
site, an ATG-less B-galactosidase neomycin fusion gene and a ploy-A site.

2 KB

E3

Gene-Trap
Gene-Trap

E4

Figure 2. Schematic representation of the strategy utilized to configure the gene-trap insertion site in
intron 3 of the Foxn3 gene. Foxn3 Intron 3 forward primers were designed at 2kB space intervals
and tested against one gene-trap specific reverse primer in WT and Heterozygous mice.
Sequencing of the PCR product indicated that the gene trap was integrated within intron 3 (15,450
bases from the beginning of the intron) of the Foxn3 gene

35

Materials and Methods
Polymerase Chain Reaction (PCR)
A nested PCR strategy was used to genotype the tail DNA of mice. Initial genotyping of
tail DNA was done by southern blot analysis, which is time consuming and
cumbersome. Gene-trap specific primers spanning 350nt (gene-trap relative positions:
1665 forward primer and 2000 reverse primer) were initially used to distinguish between
wildtype and mutant progeny. Intronic primer 3.33X was used as a forward primer and
984r was used as a gene-trap reverse primer to authenticate the insert site in the
mutant progeny. To distinguish heterozygous from nullisomic progeny, Intronic forward
primer 3.33x and intronic reverse primer 400 reverse (position relative to 400nt after
gene trap end site) were used. The PCR reaction mixture consisted of 10X PCR buffer
(50 mM KCl; 10 mM Tris-HCl final concentration), MgCl 2 (3mM final concentration),
dNTP (200μM final concentration of each), forward and reverse primers (0.4 μM final
concentration), Platinum Taq (0.5U final concentration), and ddH 20 to a final reaction
volume of 25 μl. The PCR conditions were as follows: an initial denaturation step of 5
minutes at 94°C, followed by another denaturation step of 30 seconds, annealing for 30
seconds at 58°C, and extension for 90 seconds at 72°C. This was repeated for a total of
32 cycles. A final cycle of 72°C for 5 minutes was also included. The PCR products
were run on a 1.5% agarose gel at 95 V for approximately 1 hour. Ethidium bromide
was used to visualize the bands, and the gel was photographed using the Epichem3
Darkroom and analyzed using LabWorks GelPro Application. The presence of a 350BP
band with the gene-trap specific primers or the presence of a 1.5KB band in the insert
primers indicated at least one gene trapped allele and thus heterozygousity. The lack of
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a band in the two intronic primers indicated a nullisomic progeny, while the presence of
a 1.2KB band indicated a heterozygous progeny.
PRIMERS
Primers used genotype analysis
GS1 (Forward): TGATGCTCTCTCTACCAGTGGGAT
GS2 (Reverse): ATACACAGCACCCACTCCTATCCA
TR1 (Reverse): CCCAACTGACCTTGGGCAAGAACATA

Primers used for RT PCR
Foxn3:
Forward: ATGCACCTACTGGGTGGAAGAACT
Reverse: GGCTCCGTTTCTCTTGAAGAAGGT
Foxn3-βgeo:
Forward: ATGCACCTACTGGGTGGAAGAACT
Reverse: TTTCCCAGTCACGACGTTGT
Bmp2:
Forward: TATGCTAGATCTGTACCGCAGGCA
Reverse: CAAGTTGGCTGCTGCAGGCTTTAT
Bmp4:
Forward: AGCCAACACTGTGAGGAGTTTCCA
Reverse: ACTGCAGGGCTCACATCGAAAGTT
Bmp7:
Forward: ACCGCAGCCGAATTCAGGATCTAT
Reverse: ACCATGAAGGGTTGCTTGTTCTGG
Runx2:
Forward: GTGGCCACTTACCACAGAGCTATT
Reverse: GATGAAATGCTTGGGAACTGCCTG

Rpl38 (Ribosomal protein L38):
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Forward: TTCGGTTCTCATCGCTGTGAGTGT
Reverse: TCTTGACAGACTTGGCATCCTTCC

Micro Computed Tomography (mCT) Image analysis
High-resolution CT images were acquired using a MicroCAT™ II + SPECT instrument
(Siemens Medical Solutions, Molecular Imaging, Knoxville, TN). Each image comprised
360 projections at 1 degree intervals and was acquired with X-ray source energy of 80
kVp. CT data were rendered using the Amira 3-D image analysis software package
(Amira, Version 3.1: Mercury Computer Systems, Chelmsford, MA). Foxn3 deficient
mice were isolated at 9.5, 11.5, 13.5, 18.5 day post coitum and 8,40 day old mice from
various matings. Cranium was isolated and placed in Bouin‟s fixative or 10% formalin.
Micro CT analysis were performed by Dr. Jon Wal at the University of Tennessee‟s
Medical Center.
RNA isolation and RT-PCR protocol
Total RNA was extracted using Trizol according to the manufacturer‟s instructions
(Invitrogen) from MEFS and various tissues from adult mice (3 months of age). For
expression analysis of skulls, the brain tissue was removed from neonatal mice and the
remainder of the tissues was homogenized. First strand cDNA synthesis was
performed with 2µg of total RNA (pretreated with RNAse free DNAse) with random
hexamers and M-MLV reverse transcriptase (Promega) for 1 hour at 42 oC followed by
inactivation of the reverse transcriptase at 70 0C for 15 minutes. A similar amount (2µg)
of total RNA (pre-treated with RNAse free DNAse) was subjected to the above
mentioned conditions in the absence of M-MLV reverse transcriptase. For PCR assays,
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2µl of the reaction mixture (from a total of 40 µl) obtained from the first strand cDNA
synthesis reaction was used. The PCR conditions were 94 0C for 2 min, followed by 30
cycles at 940C for 30 sec, 580C for 30 sec and 720C for 10 sec. PCR products were
resolved by agarose gel electrophoresis and stained with ethidium bromide.
Expression analysis of Foxn3 during mouse development
Embryos obtained from timed matings from wild-type females and Foxn3+/H males were
fixed with 2% paraformaldehyde and stained in a solution containing X-gal (2 mM
MgCl2, 0.01% sodium deoxycholate, 0.02% NP-40, 5 mM potassium ferricyanide, 5mM
potassium ferrocyanide, 0.1 M phosphate buffer, pH 7.3). Genotypes of embryos were
determined from genomic DNA isolated from yolk sacs.
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Results
The results of this chapter were published in a manuscript titled “Foxn3 is essential for
craniofacial development in mice and a putative candidate involved in human congenital
craniofacial defects” (124).
Published results.
Genomic DNA isolated from ES cells were analyzed by PCR to confirm Foxn3
disruption by using primers (spanning 2 kb intervals) that were specific for Foxn3 intron
3 and the gene-trap sequences. After obtaining one specific band in heterozygous DNA,
we confirmed the authenticity of the band by obtaining other forward primers in the
region and running PCR analysis to confirm the band size. Similar analysis was done
utilizing other reverse primers from the gene-trap (Figure 3). Sequencing of the PCR
product indicated that the gene trap was integrated within intron 3 (15,450 bases from
the beginning of the intron) of the Foxn3 gene.
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Figure 3. PCR analysis of multiple forward primers of intron 3 of the Foxn3 gene. Left figure shows the
banding pattern obtained from running one gene-trap specific reverse primer with multiple
forward primers in WT and heterozygous mice. Right figure shows the isolated forward primers
with variable gene-trap specific reverse primers.

After confirming the insertion site of the gene trap, we designed an intronic
reverse primer 400 BP after the insertion site. This reverse primer was designed to yield
a 1.2KB band when run with a specific intronic forward primer. This product can only be
made in the heterozygous mice because they still maintain a wildtype copy of the
FoxN3 gene (Figure 4). The insertion of the gene trap extends this 1.2Kb product to
approximately 10KB in the mutant chromosome, which is not amplified by a PCR
analysis. Therefore, our nullizygous mice will not show a product for this specific PCR.
This allows us to differentiate heterozygous versus nullizygous mice without utilizing a
southern blot.
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a. Schematic
Configuration

Heterozygous

Gene-Trap
Gene-Trap
Gene-Trap
Gene-Trap

Nullyzygous
Gene-Trap
Gene-Trap

b. WT allele
GS1

GS2
50.1 kb

3

4

18.9 kb
c. Trapped allele
GS1
3

TR1

GS2
β-gal-neo Trap (8.4 kb)

4

d. Genotype analysis

Figure 4. Schematic representation of the Foxn3 chromosome locus in wild type, heterozygous, and
nullisomic mice. A. schematic representation of forward and reverse primer pair (GS1 and GS2)
used for genotyping of Foxn3 mutant mice. B. Wildtype allele of Foxn3 intron 3 showing relative
positions of the primer pair and the gene trap. C. Mutant allele showing the Insert PCR primer pair
(GS1 and TR1) used for identifying Foxn3 mutant mice. D. Agarose gel electrophorysis analysis of
wildtype, heterozygous and nullisomic Foxn3 mice and the primer pair used for each genotype.

At the protein level, the insertion of the gene trap was determined to be within the
C-terminal portion of the Fork-head box domain and upstream of three C-terminal exons
encoding the SIN3 binding domain. The truncated FoxN3 protein yields a FoxN3-βgeo
fusion protein containing the first 218 amino acids of the 457 amino acids protein
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(Figure 5). Once we were able to genotype the mouse colony and the offspring of
matings, we analyzed the embryonic and post-natal lethality of FoxN3 mutant mice.
Analysis of Heterozygous matings at neonatal day 1 shows 61% survival of the
Nullisomic offspring which indicates some embryonic lethality (Table 1). Further analysis
of these offspring during weaning (day 21) shows a 25% survival of the null offspring,
which further confirms the lethality of the FoxN3 mutant mice.
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Figure 5. Schematic configuration of the FoxN3 gene. A. Schematic representation of the FoxN3 gene
showing its exons, introns, and gene-trap insertion site. B. NCBI analysis of the insertion site at
the FoxN3 protein. Notice the loss of the C-terminal SIN3 binding domain as well as a portion of
the Forkhead box. C.Schematic representation of the fusion protein containing the first 218 amino
acids of FoxN3 and the C-terminal βgeo fusion protein.
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Table 1. Embryonic and postnatal lethality of FoxN3 mutant mice. Neonatal pups and offspring at
weaning were genotyped for FoxN3 disruption using PCR. The total number of intercrosses (n)
analyzed for each group and the expected numbers of mice based on Mendelian ratio are
indicated within parentheses.

Developmental
stage

Total

WT

+/m

m/m
(expected)

% Survival
of m/m

Neonatal day
1 (n=9)

71

21

38(42)

13(21)

61%

Weanlings at
day 21 (n=7)
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16

35(32)

4(16)

25%

We analyzed Foxn3 expression patterns in embryos obtained from timed matings
between wild type and Foxn3 heterozygotes. Foxn3 expression was limited to the
craniofacial regions and the developing vertebral column during embryogenesis ( Figure
6). Importantly, Foxn3-β-gal expression was specific only to the heterozygotes (as

determined via the genotyping of the yolk sacs) and the wild type embryos did not show
any staining for β-galactosidase. Analysis of Foxn3 gene expression in tissues from
adult mice indicated a differential expression pattern with the highest expression in the
brain, eye, skeletal muscle, thymus and ovaries (Figure 6).
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Figure 6. Expression analysis of Foxn3 during embryogenesis. Embryos obtained from wild type and
heterozygote intercrosses at E11.5 and E13.5 were fixed in 2% paraformaldehyde, stained with Xgal overnight and photographed. Representative photographs show Foxn3 heterozygous embryos
(stained blue in panel b b, panel c (bottom), panel f and panel g and control wild type littermate
embryo Panel a, panel c (top) and panel e that were stained similarly. Panel h shows RT-PCR
expression of Foxn3 in various adult tissues.

Examination of the developing mice showed that homozygous mutants exhibited
severe runting and reduction in head circumference, which is indicative of craniofacial
developmental defects (Figure 7). The average body weights of the wild type and mutant
animals at weaning were 13.5 +0.70g (FoxN3+/+, n=3), 12.9+ 0.70g (FoxN3+/m, n=6),
and 4.7+0.43g (FoxN3m/m, n=4).
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Figure 7. Photographs of FoxN3 WT and mutant mice at P8 and P11 showing the runting phenotype.

To further characterize the microcephaly phenotypes, we performed imaging
studies of the mutant and wild type littermate controls at stages P2, P8, P10, and P11
using micro-computed tomography. A majority of the homozygous mutants and a minor
subset of heterozygotes showed cranial vault defects of the skull, delayed suture
closure and defects in the frontal, parietal and occipital bones of the skull ( Figure 8 b-d).
Subsequent histological analysis of calvariae obtained from 11 day old WT and
homozygous mutant littermates indicated a drastic reduction in calvarial bone formation
in the mutants (Figure 8 d) that was consistent with the mCT-scans that showed a
reduced density in the homozygous mutants [compare Figure 8 c (bottom panel) and
Figure 8 d]. Examination of the mandible showed reduced size and midline fusion that

prevented further growth (Figure 8 e). There were apparent midline defects indicative of
defective development of the basispehenoid, basioccipital, tympanic, and palatal bones
Figure 8 e).
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Figure 8. Craniofacial skeletal developmental defects in Ches1 mutants. A-B: Isosurface rendering of
micro-computed tomography (CT) images of the skull images of 8 day old WT and mutant pups
are shown in panels A (lateral view) and B (coronal plane of the dorsal aspect). The mutants have
reduced bone structure in the skull bones that appear as hollow structures because image threshholding was optimized for viewing the calcified structures. C: Coronal planar view through base
of skull. D: CT scan comparison of 11 day old wt and homozygous mutant pups. E: Volume
texture rendering of microCT images of 2 day old wild type and mutant littermate pups shows
retarded growth of the mandible which appears to be fused at the midline prematurely. For
comparison, the premaxillary area (1), basispehenoid (2), basioccipital (3), and tympanic bones (4)
are indicated in the WT animal on the left. High-resolution CT images were acquired using a
MicroCAT™ II + SPECT instrument (Siemens Medical Solutions, Molecular Imaging, Knoxville,
TN). Each image comprised 360 projections at 1 degree intervals and were acquired with an x-ray
source energy of 80 kVp. CT data were rendered using the Amira 3-D image analysis software
package (Amira, Version 3.1: Mercury Computer Systems, Chelmsford, MA).
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We also performed histological analysis of the calvaria in 11 day old wildtype and
null mutants which show a reduction in the thickness of the calvaria in the mutant
animals (Figure 9).

Figure 9. Histological assessment of calvaria in 11 day old wild type (left) and homozygous mutant (right)
littermates. Notice the calvaria is reduced in thickness in the mutant mouse. Saggital sections of
the skull were made stained by hematoxylin and eosin and photographed at the same
magnification (20X). Identical areas of the same width and length beginning from the connective
tissue of the scalp are shown. The drastic reduction in the skull bone thickness of the mutant
allows for visualization of a portion of brain in the mutants whereas the same are in the wild type
consists only of the skull.
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Furthermore, a subset of mutant animals exhibited eye migration defects. When
we compared 13.5 d.p.c wildtype and null mutant embryos, we noticed a cranium
development problem, microencephaly, and eye migration problems and size reduction
(Figure 10).

FoxN3 +/+
m/m

FoxN3

E13.5

FoxN3
FoxN3
+/+ +/+
m/m
m/m

FoxN3 FoxN3

E14.5

Figure 10. Compound microscope images of 13.5 and 14.5 d.p.c. wildtype and null embryos. In the left
figure, FoxN3 null embryo exhibits microencephaly phenotype along with eye size reduction and
migration defect. In the right figure, FoxN3 null embryos show a great reduction in eye size that
could be linked to an eye migration defect.
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In addition to the craniofacial defects, among the small fraction of the surviving
homozygous mutants and the heterozygotes, a high percentage of the mutant mice also
presented malocclusion due to elongated incisors. Examination of 5 month old adult
mutant mice indicated an overall growth retardation of the mutants and scoliosis like
phenotype (hunch-back spine) in comparison to WT littermates. To correlate the
phenotypes of the FoxN3 mutant mice, we performed a comparative analysis of human
patients with congenital disorders and deletions of the human FoxN3 chromosomal
locus (14q32.11) reported in the literature. Interestingly, there was a substantial overlap
of the clinical features of human patients and the FoxN3 mutant mouse model further
underlining the importance of FoxN3 in craniofacial development (Table 2. Phenotype
comparison of human patients with 14q deletions and FoxN3 mutant mice.).
Table 2. Phenotype comparison of human patients with 14q deletions and FoxN3 mutant mice.

Clinical feature

14q deletions

FoxN3 mutant

(humans)

mice phenotypes

Growth Retardation

+

+

Microcephaly

+

+

Eye deviations

+

+/-

Eye lid opening defects

+

+/-

Dental abnormalities

+

+

Ear abnormalities

+

ND

Scoliosis

+

+

Jaw abnormalities

+

+

Renal abnormalities

+

ND
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To examine the mechanism by which FoxN3 affects craniofacial development,
we tested the expression of several genes known to regulate bone morphogenesis.
Total RNA was extracted from cranium of P0 wildtype and homozygous mutant mice
and cDNA was synthesized. FoxN3 levels were reduced in FoxN3 null mice compared
to wildtype; however, there was leaky expression of the wildtype mRNA (Figure 11).
This leaky expression could be beneficial as the FoxN3 gene may act as a hypomorphic
allele, and the complete knockout of FoxN3 may cause the death of homozygous
mutant mice during embryogenesis. Additionally, FoxN3 homozygous mutants showed
reduced expression of the Bone morphogenetic proteins 2 and 4 (Bmp2 and Bmp4)
compared to the wildtype littermates (Figure 11). Similar expression patterns were
shown in mouse embryonic fibroblasts (MEFs).

Figure 11. Reduced expression of osteogenic genes in Foxn3 mutant mice and cell lines. Total RNA
was isolated from neonatal (P1) skulls (a) and MEFs (b) of wild type and homozygous mutants.
RT-PCR analysis was performed with primers specific for the indicated genes and the housekeeping gene encoding the ribosomal protein 38 (last panel).
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Discussion
Role of Foxn3 in Mammalian Development
The culmination of our data indicate that the Foxn3 gene plays a crucial role in
mouse development as the hypomorphic mutant mice displayed craniofacial
developmental defects that lead to embryonic and postnatal lethality. The craniofacial
developmental defects in the Foxn3 mutants are also correlated with the craniofacial
tissue specific expression of Foxn3 during embryonic development. Furthermore, the
phenotypes of the Foxn3 mutant mice are consistent with recent studies that have
shown the involvement of Foxn3 in craniofacial and eye development in X. laevis (122).
More importantly, the comparative analysis of the phenotypes of the Foxn3 mutant
mouse model with the clinical features of human patients with deletion of the FOXN3
locus shows a substantial overlap of the phenotypes that provide initial clues to the role
of FOXN3 in craniofacial development and underline its importance in mammalian
development (Table 2).
The mouse model we have described was generated utilizing the gene-trap
strategy and involves the random disruption of genes in mouse embryonic stem cells.
There are many advantages and disadvantages to choosing the gene-trap approach
over the conventional knockout strategy. The gene-trap is a cost efficient, high
throughput technology that allows the phenotypic screening of many genes in a short
amount of time (125). The Engrailed-2 intronic sequence simulates the intronic region
present in a mouse intron, which allows for the spliceosome machinery to bind and
recognize the sequence. The splice acceptor (SA) site adds the last exon in-frame to an
ATG-less B-galacotsidase-neomycin gene followed by a stop codon and a ploy
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adenylated tail. Upon efficient splicing of the gene into the gene trap, exons upstream of
the gene-trap will be fused in-frame to the B-galacotsidase neomycin gene and express
a fusion protein while the remainder exons will not be translated. Nevertheless, this
fusion protein can cause a dominant-negative phenotype as reported by our group or
may result in the loss of cytoplasm-nuclear shuffling (126). Although gene-trap based
mutations can give rise to the dominant-negative phenotype, a classical homologous
recombination based germ-line knockout can give rise to a similar phenotype as was
the case in Terry Van Dyke‟s attempt to remove exons 2 and 3 from the Bub1 gene
(127). However, an inefficient splicing of the upstream exon in to the downstream exon
(via the circumvention of the splice acceptor present in the gene-trap) has been shown
to occur in a minor percentage of gene trap mutants by our group and others (126, 128).
Yet, this leakiness in the gene-trap allows for examining the functions of genes which
will be lethal in null progeny (e.g. Bub1) (129). Another advantage for using the genetrap is the tissue-specific reverseal of the gene trap by the expression of a Cre
recombinase that clips two LoxP sites flanking the SA site. The Cre recombinase is
driven by the binding of a tissue-specific protein to activate the Cre-gene promoter.
Interestingly, our data shows that the Foxn3 gene trap is not completely efficient
in disrupting the expression of Foxn3 as the homozygous mutant tissues do express the
wild type mRNA albeit at low levels ( Figure 11). This leaky expression of the native
Foxn3 gene in the homozygous mutants further explains the partial lethality and
segmental craniofacial defects of the homozygous mutants. More importantly, the
hypomorphic alleles generated by gene trap mutants provide a novel opportunity to
study the role of gene function(s) at the organismal level that provide data on the
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developmental mechanisms involving heterotypic cell-cell interactions. Such analyses
are not possible with knock-out mouse models that suffer from disadvantages relating to
embryonic lethality phenotypes or conditional mutants that are not amenable to
functional studies involving cell and tissue specific heterotypic interactions during
mammalian development.
Expression Analysis of Foxn3 in Developing Embryo
The β-galctosidase fusion protein present in the gene trap is advantageous as it
allows visualization of the expression of Foxn3 during development. β-galactosidase
breaks down X-Gal into 5-bromo-4 chloroindole which gives a bright blue color. Since
the expression of β-galctosidase is correlated to Foxn3 expression, color change will
only occur in specific tissue that express Foxn3. Figure 6 shows a specific expression of
Foxn3 in the developing cranium and neural tube (brain, and spinal cord) of E13.5
embryos. We were able to see high expression of Foxn3 in the eyes of E11.5 and E13.5
embryos (Figure 6, and data not shown). It was during the examination of these embryos
that we noticed many of the phenotypes previously associated with Foxn3 mutations.
Figure 10 shows stereomicroscope images of wildtype and Foxn3 mutant E13.5 and
E14.5 embryos. Comparison of littermate embryos shows microcephaly and cranium
development defects in the mutant embryos compared to the wildtype embryos.
Furthermore, the null embryos exhibit great reduction in eye size and eye migration
defects which can be linked to cranium development defects. We could not attribute the
reduction in eye size to reduction in cell proliferation, cell mass, or increased apoptosis;
however, Schuff and his group indicated an increase in apoptosis in FoxN3 depleted X.
laevis (122).
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Foxn3‟s importance in development is demonstrated by the embryonic and postnatal lethality of Foxn3 mutant mice (Table 1). Matings of Foxn3 heterozygous mice
indicated 61% survival of the nullizygous offspring at day 1, which indicates
developmental and embryonic lethality. However, at weaning (day 21), only 25% of
nullizygous mice survived, which indicates more developmental and post-natal lethality
in Foxn3 mutant mice. Most of the nullizygous mice died by post-natal day 3, and many
of the nullizygous mice that survived exhibited a runting phenotype when compared to
littermate heterozygous or wildtype mice ( Figure 7). Measurement of the body mass of
Foxn3 null mice indicated a three fold reduction when compared to wildtype littermates.
An interesting pattern that emerged from expansion of the null mice colony was the
increased survival of pups born from homozygous null mutants; we observed a high
number of mice that survived through weaning which contrasted with the post-natal
lethality (data not shown). Foxn3 expression of nullizygous postnatal day 1 mice
generated from null crossings was much higher than the expression of similar mice
obtained from heterozygous intercrosses ( Figure 11a, and data not shown). This can be
attributed to variable expressivity of a gene where individuals with the same genotype
can display differing phenotypic characteristics (130).
The underlying etiology of the post-natal lethality in Foxn3 mice was not
determined, but previous work on X. laevis and our observations on average body mass
may yield clues. Schuff and colleagues reported lost or deformed cranial nerves in X.
laevis including hypoglossal and branches of the trigeminal nerve innervate the lower
jaw. Moreover, they reported on the death of X. laevis embryos by stage 50 for reduced
food intake. The loss of innervation of the lower jaw signifies reduced orifice function
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and thus reduced food intake. The loss of lower jaw movement has more severe effects
in a developing mouse as it initially has to suckle from the mother to feed and later chew
solid food to feed and develop. The runting phenotype in our Foxn3 null mice can be
explained by their reduced food intake due to reduced lower jaw function or
misalignment of the jaw. We have also observed that some of our heterozygous and
null mice die from abnormal growth of the incisors or malocclusion (data not shown).
Perhaps the most significant finding of my work was the role of Foxn3 in
mammalian craniofacial bone development. High resolution micro CT images of 8 day
old and 11 day old wildtype and mutant pups shows reduced bone structure and density
in the skull of Foxn3 mutant pups compared to wildtype littermates ( Figure 6 A,B). mCT
analysis also show absence or reduced bone structure on the oremaxillary area, the
basisphenoid bone, the basioccipital bone, and the tympanic bone in 2 day old Foxn3
mutant pups (Figure 6 E). We confirmed the bone density defect in Foxn3 mutant pups
by histological evaluations of calvarial cross-sections, and we noticed severe reduction
of the thickness of the calvaria and skull bones in the mutant pups ( Figure 9). The
underlying etiology of the reduced bone density in Foxn3 mutant mice could be
attributed to variation in the osteoclast to osteoblast ratio in Foxn3 mutants or
developmental defect in osteoblast differentiation leading to reduced calcification of
cartilage (131). Therefore, we examined the expression profile of prototypical genes
involved in osteogenesis that may have been deregulated in Foxn3 mutant mice. As
shown in Figure 11, the expression of bone morphogeneic proteins 2,3,4,7 and Runx2
were all down regulated in Foxn3 mutant skulls compared to wildtype littermates. Even
more, the down regulation of these genes is consistent in Foxn3 mutant mouse
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embryonic fibroblasts (MEFs) generated from other heterozygous crosses. These genes
were tested because they have been shown to play a role in osteogenesis and also
contained a Forkhead protein consensus sequence of [(A/G)(T/C)AAA(C/T)A] in their
proximal promoter (132, 133).
Craniofacial Development and FOXN3
The mouse skull is composed of frontal, parietal, interparietal and occipital bones
that have specifically evolved to surround and protect the brain. These skeletal
components receive lineage contributions from both the cranial neural crest cells and
the paraxial mesoderm, both of which migrate to defined locations overlying the brain
and subsequently differentiate into osteogenic and chondrogenic mesenchyme between
embryonic stages E7.5 and E11.5 (132). The evolution of neural crest cells has been
postulated as the foundation for the initial appearance and evolutionary expansion of
vertebrates as it is unique to vertebrates (134). The skull vault primarily develops by
intramembranous ossification, characterized by direct differentiation of the osteogenic
mesenchyme into osteoblasts as opposed to endochondral ossification. During skull
development, the margins of each bone anlage are populated by highly proliferative
osteoprogenitor cells thereby maintaining calvarial expansion (135). By E15.5 the
individual skull bones have acquired their basic structure and are separated by sutures
which are composed of fibroblasts and skeletal mesenchyme. Calvarial bone growth
and expansion is coordinated by the growth of the brain through continued production of
the osteoprogenitors present within the suture (135). Several growth factors and
transcription factors have been implicated in craniofacial and skeletal development
(133, 136, 137). Of these, the fibroblast growth factors (FGF) and a number of
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homeodomain proteins (Msx2, Dlx5, Engrailed 1, and Alx4) have been shown to
regulate calvarial bone development (138, 139). Evidence indicates that the
spatiotemporal expression of several of these growth and transcription factors and their
interactions with each other regulate craniofacial skeletal development. The reduced
expression of the osteogenic genes in the craniofacial tissues of the Foxn3 homozygous
mutants suggests that the Foxn3 protein activates the expression of genes necessary
for osteogenesis and plays a regulatory role in the craniofacial skeletal development.
However, the molecular mechanism(s) of the aberrant expression of osteogenic genes
in the Foxn3 mutants remain to be ascertained. Interestingly, the FOXN3 protein has
been shown to associate with Sin3, a component of the Sin3/Rpd3 histone deacetylase
complex (HDAC) in budding yeast and inhibit the activity of Sin3/Rpd3 HDAC complex.
The Sin3 complex is targeted to specific promoter regions via Sin3 interactions with sitespecific DNA-binding proteins. Our data suggests that the loss of osteogenic gene
expression in the Foxn3 mutants is potentially due to the loss of inhibition of Sin3
complex that can in turn lead to deacetylation of histones within the promoters of the
osteogenic genes resulting in their repression. Nonetheless, a direct role for Foxn3 in
the transcriptional activation of specific genes necessary for craniofacial development
cannot be ruled out as the interaction studies have utilized heterologous systems
(FOXN3 is not coded in the yeast genome). Furthermore, the interaction of Foxn3 with
the transcriptional adaptor SKIP suggests that its role in the transcriptional regulation of
its target genes might involve and be dictated by its interacting partners in a cell type
and tissue specific manner. It is noteworthy that that the transcriptional activation and
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repression functions of other Fox proteins have been shown to be cell-context
dependent (92).
Correlation of Foxn3 and Human Disease
Our assessment of the role of Foxn3 in developmental disease significantly
correlates with congenital and developmental defects in human patients with deletions
of chromosomal region 14q32.11 ( Table 2). The most observable phenotypes were the
growth retardation, eye deviations, scoliosis, and jaw abnormalities including
malocclusions. Moreover, we observed abnormal kidney morphology and function as
we performed necropsies on Foxn3 heterozygous and null adult mice, but we have not
yet confirmed these observations by histological assessments. The remarkable overlap
of phenotypes in Foxn3 mutant mice and human patients with FOXN3 locus deletions
signifies the conservation of the role of Foxn3 in mammalian development and may
provide an underlying mechanism of human disease. Indeed, expression of bone
morphogenic protein 4 (BMP4) in mice has been shown to increase bone fractures
healing time and bone density (140). Moreover, Wright and colleagues showed that
muscle derived stem cells are capable of undergoing osteogenic lineage differentiation
when transfected with BMP4-encoding retrovirus (141). This suggests that ectopic
expression of BMP4 may be utilized to treat patients with craniofacial bone development
defects or such application may be used to treat human patients with facial bone
fractures or breaks. However, we have not yet evaluated the underlying molecular
mechanism that FOXN3 utilizes to regulate bone morphogenic factors expression.
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Chapter III
FOX Proteins, Cell-Cycle Regulation and Tumorgenesis
Previous studies on FOX proteins and cancer
The forkhead family of proteins has undergone an evolutionary expansion in
higher eukaryotes and mammals compared to C. elegans and Drosophila (142). This
allows adaptation of FOX proteins to the increased developmental and tissue
complexity required in higher organisms. FOX members have been shown to play
diverse roles in development, immune system, apoptosis, cell cycle control, cancer, and
invasion of metastatic tumors (143). FOX proteins are terminal effectors for many
signaling pathways, and mutations in FOX proteins perturb proper activation of these
pathways to maintain homeostasis. Correlation of gene function can be made through
in-vivo studies on rodent models because all human FOX genes have orthologues in
mouse, except for FOXD family which has one member (Foxd1) in mouse but seven
members in humans due to a recent duplication (144). Mutations in several Fox
subfamilies (FoxA, FoxC, FoxL, FoxM, FoxO, and FoxP) have been shown to promote
tumorogenesis in mouse models in a specific or redundant form. FoxC proteins are
involved in the development of vascular system, and are correlated to cancer through a
role in vascular angiogenesis (142). FoxL1 is expressed in the messenchyme of the GI
tract and null mutation to Foxl1 reduced epithelial cell proliferation due to disrubtion of
the Wnt pathway in this organ. Furthermore, Apc+/Min;Foxl1-/- mice showed higher tumor
load in the colon compared with APC+/Min;Foxl1+/+ and Apc+/Min; Foxl1+/- mice thus
showing synergistic effect of mutations in adenomatous polyposis coli (APC) gene and
Foxl1. This suggests that some FOX genes can be deregulated during tumorogenesis
but may not be able to initiate it on their own. There are a few FOX family members that
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regulate cell-cycle processes and can thus be considered true tumor suppressor genes
or proto-oncogenes (93).
FOXM family
FOXM1 is a proliferation-associated transcription factor that promotes S-phase
entry and proper execution of mitosis in rapidly dividing cells (99, 145). FOXM1 gene is
up-regulated in pancreatic cancer and basal cell carcinoma due to the transcriptional
regulation by Sonic Hedgehog (SHH) pathway (142). FOXM1 has splice variant proteins
that play a crucial role in mitosis and G1/S phase and G2-M cell-cycle progression
through regulation of different proteins. Foxm1b transcription factor is essential for liver
development, hepatoblast regeneration and hepatocyte mitosis during liver
morphogenesis. Conditional deletion of Foxm1b results in diminished DNA replication
and failure of hepatoblast to enter mitosis due to decreased levels of Polo-like kinase 1
and Aurora B kinase, which regulate proteins during mitosis (145). Foxm1b also
regulates the induction of c-Myc, c-Fos, and cyclin-B, all associated with cell
proliferation and S-phase entry (145). The splice variant FOXM1a binds the same DNA
sequences as FOXM1b, but does not trans-activate genes (146). In human studies, the
FOXM1 gene is located on the chromosomal locus 12p13, a region typically amplified in
breast adenocarcinomas, head and neck squamous cell carcinomas, and cervical
squamous carcinomas. This region also contains CDKN1B (encodes p27), so it remains
possible that FOXM1 may not initiate tumorogenesis, but rather enhancing its
progression (142).
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FOXO family
The FOXO family is considered to function as a tumor suppressor family through
promoting cell cycle arrest and apoptosis. FOXO family expression varies between cell
types or organs. FoxO1 is highly expressed in adipose tissue, while FoxO4 is in muscle
and FoxO3a in liver and FoxO6 is exclusively in brain. All FoxOs bind to the same
FOXO recognition element 5‟-(G/C)(T/A)AA(C/T)AA-3‟ and can essentially regulate the
same set of genes through binding of this motif. The FOXO family plays a dual role as
transcriptional activators and transcriptional repressors, and they exhibit nuclear
shuttling by having nuclear localizing sequence (147, 148).Initial correlation of FOXO
family with cancer was revealed in translocations in tumors especially in alveolar
rhabdomyosarcoma where a translocation in (2;13) and (1;13) results in PAX3-FoxO1
and PAX7-FoxO1 fusion proteins (142). Since then, studies in mice have revealed that
single FoxO mutant mice form mostly neoplasias while triple mutants (FoxO1, FoxO3A,
FoxO4) can induce Myeloid-lymphoid leukaemia (MLL) and thymic lymphomas, thus
exhibiting redundancy and compensation in the FoxO subfamily (149). FOXO family
protein regulate cell cycle arrest and apoptosis by regulating the expression of cyclindependent kinase (Cdk) inhibitors p27 Kip1 and p21Waf1 or repressing the expression of
Cyclins D1 and D2 (150). FOXO family proteins are involved in glucose homeostasis
and activation of multiple insulin-responsive genes; FOXO are targets for PI3K-Akt
mediated phosphorylation to regulate glucose homeostasis (84). Phosphorylation of
FOXO family protein by Akt protein kinases causes the retention of FOXO proteins in
the cytoplasm, thus allowing for cell cycle to proceed (148).
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FOXP family
The FOXP family members have been implicated to function as either oncogenes
or tumor suppressor genes, depending on various contexts. FOXP family members
have been shown to play roles in immune response regulation, B-cell development,
tumorogenesis, and neuronal development (151-153). A well-known member of this
family is FOXP2, which is associated with many developmental disorders most notably
speech and expressive language impairments, but has not been associated with cancer
(154). FOXP1 was the first member of this family to be cloned, and differently from
FOXO family members, is expressed in all tissues. In several subtypes of B-cell nonHodgkin lymphomas, high-level FOXP1 protein expression is achieved through
recurrent chromosome translocations involving the FOXP1 locus and is a marker for
poor prognosis for patients (155). Alternative splicing leads to N-terminal truncations of
FOXP1 and over expression of short oncogenic isoforms of FOXP1 in diffuse large Bcell lymphoma (DLBCL) (153). Alternatively, nuclear expression of FOXP1 in breast
tumors was associated with improved patient survival, and thus was predicted to
function as a tumor suppressor protein (156). FOXP1 and FOXP2 have also been
shown to act as repressors on genes involved in lung morphogenesis (157). FOXP3 is
the last member of the FOXP family, and it‟s been linked to the immune dysregulation,
polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) (158). FOXP3 attenuates
the expression of cytokine necessary in T cell development by repressing the activity of
nuclear factor of activated T-cells (NFAT) (159). FOXP3 is a transcriptional repressor of
the onco-protein c-Myc, and somatic inactivation or deletion of X-linked FOXP3 has
been observed in patients with prostate cancer (160). Additionally, FOXP3 loss of
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expression is observed in aggressive breast cancer in humans, and predisposes mice
to breast cancer (93).
FOXN3 and cancer
Comparative real-time RT-PCR studies have shown that FoxN3 (Ches1) is
under-expressed in 46% of human oral squamous cell carcinoma samples, and its
expression was decreased by 15 fold in OSCC tissue with a concomitant overexpression of CDK1, NPM and NDRG1 (161). Ches1 and CDK1 were predicted to be
linked in a regulatory network during tumorogenesis (161). Ches1 was also underexpressed in clear renal cell carcinomas (cRCC) compared to normal tissue (162). In a
study of laryngeal carcinoma markers, Ches1, along with ADAM-12, CDK2, and KIF-14
were found to be good specific markers for this cancer (163). The down-regulation of
FOXN3 in malignant tissues, along with the finding that human FOXN3 recruits SKIP to
repress transcription, indicate that certain oncogenes regulated by FOXN3 may be overexpressed in cancer cells due to decreased FOXN3 levels (116). To further investigate
a possible role for FOXN3 in initiating tumorogenesis, we analyzed the heterozygous
and some homozygous Foxn3-mutant mice for survival and tumor formation over two
years time period.
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Materials and Methods
Generation of Foxn3 mutant mice
Foxn3 mutant mice were generated and maintained as previously described (124).
Upon signs of morbidity, mice were euthanized and organs were harvested and saved
in 10% formalin solution. Wild type, heterozygous mutant, and nullizygous mutant mice
(n= varies) were irradiated with X-ray radiation (7 Gray, 2 Gray/week) beginning at 4
weeks old. Upon signs of morbidity, mice were euthanized and necropsy was performed
to check for tumors.
Generation of Mouse Embryonic Fibroblasts.
MEFs were derived from 13.5-day-old Foxn3+/+, Foxn3+/m and Foxn3m/m embryos.
After removal of the intestinal organs, each embryo was washed with PBS (Gibco) and
minced using 18 gauge needles. Cells were cultured in Dulbecco‟s modified Eagle
medium with high glucose (HyClone, South Logan, Utah, USA) supplemented with 2mM
L-glutamine, 1X antibiotic-antimycotic, 1μl/ml of fungizone (Invitrogen, Carlsbad, CA) ,
and 15% heat-inactivated fetal bovine serum (Gibco). Primary cells were frozen in
aliquots after the first passage.
Immortalization of Foxn3 MEFs
Foxn3 +/+, Foxn3 +/m, Foxn3m/m MEFs were immortalized by transforming the cells
with SV-40 (simian vacuolating virus 40) large T antigen containing plasmid
pBSSVD2005. Primary Foxn3 passage 2 MEFs were plated at 50% confluency in a
100mm plate and cells were transiently transfected with pBSSVD2005 using Turbofect
reagent (Fermentas, Glen Burnie, MD) according to the manufacturer‟s instructions.
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When the cells were just confluent, they were split at a dilution of 1/10. The cells were
continued to be split at 1:10 dilutions till passage 5. This type of splitting ensured a
strong negative selection against non-transformed cells.
Clonogenicity Assay
SV-40 immortalized Foxn3 +/+, Foxn3 +/m, Foxn3m/m MEFs (2.5X10 3) cells were
seeded in complete media and treated with 10 J/m2 UV radiation or exposed to 4 Gy
dose of X-ray radiation 24hrs after seeding. After ~8 -10 days, the plates were stained
with coomassie blue and colonies were counted using a stereomicroscope. The
colonies from the various treatments were normalized to the untreated control. For each
treatment, the cells were plated in four 60mm2 plates. The whole experiment was
repeated twice using two independently derived cell lines.
RNA Interference Transfection
RNAi oligonucleotides were obtained from IDT DNA (F-LUC-Si, FOXN3) and
resuspended in nuclease-free water to a concentration of 40µM. HCT116 cells were
plated in 60mm-well plates in DMEM media containing 10% fetal bovine serum to give
30–50% confluence. Transfection of the RNAi oligonucleotides was performed using
Trifectin (IDT-DNA) to result in a final RNA concentration of 40 nm. The cells were
harvested at different time points and lysed in BE lysis buffer plus 1mM PMSF (40mM
NaCl, 20mM Tris-HCl pH 7.8, 2mM MgCl2, 0.5% NP40, Benzonase (Novagen,
250U/mL) for Western blot analysis. siRNA sequences were:
F-Luc si: 5'-rGrCrA rUrArU rCrArA rArGrC rArCrA rUrCrA rGrGrU rCrCA C-3'
5'-rGrUrG rGrArC rCrUrG rArUrG rUrGrC rUrUrU rGrArU rArUrG rCrCrU-3'
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Foxn3: 5- rGrCrA rUrArU rCrArA rArGrC rArCrA rUrCrA rGrGrU rCrCA C -3
5'-rGrUrG rGrArC rCrUrG rArUrG rUrGrC rUrUrU rGrArA rUrGrC rCrU-3'
Western Blot
HCT116 cells were scraped in phosphate-buffered saline (PBS), pellet at 1‟400 RPM,
and lysed in BE lysis buffer plus 1mM PMSF (40mM NaCl, 20mM Tris-HCl pH 7.8, 2mM
MgCl2, 0.5% NP40, Benzonase (Novagen, 250U/mL). Cell lysates were mixed with
reducing Laemmli sample buffer, separated on 8% or 12% SDS–polyacrylamide gels
and transferred onto PVDF membranes (Thermo scientific). Membranes were blocked
at room temperature for 2 hours in TBS-Tween (100mM Tris-HCl, 200mM NaCl, 0.1%
Tween 20) with 5% milk, and incubated with primary antibody overnight at 4 oC or at
room temperature for 2 hours. After washing with TBS-T, membranes were incubated
with horse radish peroxidase-conjugated secondary antibody for 1 hour at room
temperature in TBS-T containing 2% milk. Signal was visualized with the Super Signal
chemiluminescent reagent (Thermo scientific).

Reagents and Antibodies
Cell culture reagents were obtained from the following sources: fetal calf serum and
Antibiotic-Antimycotic (Gibco, Invitrogen). Antibodies were obtained from the following
sources: FoxN3 (Santa Cruz Biotechnology, Santa Cruz, CA; sc-54257), Cyclin-B1,
Cyclin-D1, CDK2, CDK1 (CDC2), Beta-Tubulin (Gentex, Zeeland, MI).
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Statistical analyses and survival curves
Standard error, mean and P-values were determined using the statistics software from
Microsoft Excel. Kaplan–Meir survival curves were generated and analyzed with Prism
4 (GraphPad Software).
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Results
3.1. Characterization of tumorogenesis in Foxn3 mice
The mutant offspring that survived beyond the perinatal stage did not show any
overt developmental abnormalities except for a pronounced reduction in size at weaning
but was less apparent in 3–4 months old mice. However, after 7–12 months of age, the
heterozygous and homozygous mutant mice began to exhibit weight loss, lordokyphosis
(hunch-back spine) and loss of vitality. Survival analysis showed drastic reduction in the
lifespan of the Foxn3 heterozygous (+/m) and homozygous (m/m) mutant mice (median
lifespan of 80 weeks for heterozygous, median lifespan of 64 weeks for homozygous)
(Figure 12). Histological examination of organs harvested from morbid mice showed that
a majority of the mice were succumbing to splenic or thymic lymphomas with a minor
fraction of adenomas and sarcomas (data not shown). The earliest incidence of
lymphomas in the mutant mice was at 26 weeks of age. 50% of nullizygous mutants
(8/16) exhibited spontaneous tumor formation and 43% in heterozygous mutants
(13/30). In comparison, only 25% of wild-type mice were diagnosed with a tumor during
the analysis period (4/12). Wild-type mice also develop lymphomas as a function of age,
and such tumors account for about 5–20% incidence as reported for mice of various
genetic backgrounds by others (164).
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Figure 12. Survival Curve of Foxn3 mice. Kaplan–Meier survival curves of Foxn3 mutant and wild-type
littermates (n=20 +/+ , n=47 +/m , n=16 m/m). The percentages of survival are plotted as a function
of age in weeks. Animals were monitored for tumors, morbidity or spontaneous death over a
period of 105 weeks. Of the animals analyzed for each group (numbers mentioned above), 40 of
the heterozygous mutants died, all 16 of the nullizygous mutants died in comparison with 9 for the
wild-type controls during a period of 2 years. The differences in the lifespan of wild type and
mutant animals were statistically significant (p<0.0001). All mice were of mixed inbred
C57BL/6X129/Sv background.

Additionally, we wanted to assess whether Foxn3 plays a role in DNA damage response
or cell-cycle progression in mice. Therefore, we treated 4 weeks old wild type (WT),
heterozygous mutant (Het) and homozygous mutant (Null) with 7 Gray X-ray radiation
(1.75 Gy/week, 4 weeks) and checked for signs of lethargy, tumor formation, or death.
Survival analysis showed drastic reduction in the lifespan of the Foxn3 heterozygous
(Het) and homozygous (Null) mutant mice (median lifespan of 28.28 weeks for Het,
median lifespan of 28.84 weeks for Null) compared to wild-type littermates (median
lifespan of 60 weeks) (Figure 13). The earliest incidence of lymphomas in the mutant
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mice was at 13 weeks of age. The difference in lifespan between the mutant animals
and wild-type littermates was statistically significant (P<0.01), but there was no
statistical significance between heterozygous and nullizygous mutant animals (similar
median lifespan).
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Figure 13. Survival analysis of Foxn3-deficient mice after IR treatment. Kaplan–Meier survival curves
of Foxn3 mutant and wild-type littermates (n=9 Wt , n=13 Het , n=14 Null). The percentages of
survival are plotted as a function of age in weeks. Animals were monitored for tumors, morbidity
or spontaneous death over a period of 66 weeks. Of the animals analyzed for each group
(numbers mentioned above), all 13 of the heterozygous mutants died, all 14 of the nullizygous
mutants died in comparison with 6 for the wild-type controls during a period of 66 weeks (all
animals were terminated at 66 weeks). The differences in the lifespan of wild type and mutant
animals were statistically significant (p<0.01). All mice were of mixed inbred C57BL/6X129/Sv
background.

3.2. Impaired DNA repair in Foxn3 deficient MEFs
Transformation of normal rodent cells into tumorogenic cells requires the
deregulation of genes that control cell growth and differentiation. Several genes can be
upregulated in combinations to produce this phenomenon (i.e. activated Ras and Myc,
activated Ras and activated E1A, simian virus SV40 large T antigen) (165). We used
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SV40 large T-antigen transformed Foxn3 MEFs to perform a clonogenicity assay to test
the long term survival of MEFs after DNA damage (UV and X-ray radiation). SV40
transformed Foxn3 mutant MEFs were strikingly hypersensitive to UV and X-ray
radiation treatment compared to wildtype MEFs (Figure 14). These observations signify
that immortalization of Foxn3 heterozygous and homozygous mutant MEFs makes them
vulnerable to UV and X-ray radiation DNA damage, which in turn reduces their
clonogenic survival.
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Figure 14. Clonogenicity assay of Foxn3 MEFs. SV40 transformed wildtype (+/+), heterozygous (+/m)
and homozygous (m/m) MEFs were seeded and treated with 10 J/m2 UV radiation or 4 Gy dose of
IR. Colonies were counted after 8-10 days. The percentage of untreated cells was set at 100%.
Error bars represent SD values for quadruplet samples. Heterozygous and homozygous mutant
MEFs were statistically significant compared to wildtypes (p<0.05).
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3.3. FOXN3 deficiency deregulates cell-cycle regulatory proteins
RNA interference was effective in reducing FOXN3 protein levels in HCT116
cells. We checked the protein levels of cell-cycle progression proteins including CDK1
(CDC2) and CDK2, Cyclin-B1, Cyclin D1, and Retinoblastoma for any deregulation of
expression due to loss of FOXN3. The levels of Cyclin-B1 and CDK2 proteins were
reduced in FOXN3 deficient cells compared to F-Luc controls (Figure 15). Meanwhile,
Cyclin-D1, Cdc2 (CDK1), and Rb protein levels were not changed due to FOXN3
deficiency, indicating a specific effect of FOXN3 on cell cycle progression proteins.
Beta-Tubulin indicates equal loading of cell lysates.

Figure 15. Western blot analysis of cell-cycle progression proteins after RNAi-mediated knockdown of
FOXN3. FOXN3-specific RNAi was efficient in reducing FOXN3 levels in HCT116 cells 48 hours
after transfection. Cyclin-B1 and CDK2 proteins were reduced in FOXN3 deficient cells,
meanwhile, Cyclin-D1, Cdc2 (CDK1), and Rb protein levels were not changed due to FOXN3
deficiency. Beta tubulin indicates loading control.
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Discussion
The data accumulated thus far indicates a role for Foxn3 in tumorigenesis as
heterozygous and homozygous mutant animals exhibit a decreased lifespan and
increased spontaneous tumor susceptibility. The majority of the mice succumbed to
splenic or thymic lymphomas with some cases of adenomas and sarcomas. This is the
first mouse model that studies the role of Foxn3 in initiating tumorigenesis in mammals.
All previous reports have shown deregulation of FOXN3 expression in human patients‟
cancer samples, but never a role for Foxn3 as a true oncogene or tumor suppressor
gene (161). Additionally, Foxn3 deficiency can enhance tumorigenesis in mice that have
been treated with ionizing radiation (IR) to initiate tumors. Exposure of mice to IR leads
to DNA double stand breaks (DSB‟s), which if left unresolved, can lead to
rearrangements and aberrations of chromosomes, thus leading to genomic instability
and initiate cancer formation (28, 166). This data suggested a possible role for FOXN3
in DNA repair or regulation of cell-cycle progression. To investigate the underlying
mechanism of Foxn3-mediated tumorogenesis, we performed a clonogenicity assay to
test the long term survival of Foxn3 mutant MEFS after DNA damage. The colony
forming competency of Foxn3 mutant MEFs was greatly compromised after UV and Xray radiation treatments, which may suggest a role for Foxn3 in the DNA damage repair
pathway. However, more experiments are required to further prove the role of Foxn3 in
DNA damage repair. Interestingly, we have performed a cell proliferation assay and
results indicate a tremendous proliferation capacity for the heterozygous MEFs, while
the homozygous and wild type MEFs maintain the same growth kinetics over the same
time (data not shown). However, we have not been able to generate three independent
MEF cell lines to cover the biological replicas to prove this data.
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To determine a functional mechanism for FOXN3 in tumorogenesis and cell-cycle
regulation or DNA repair pathways, we checked the levels of specific cell-cycle
checkpoint proteins that have either been reported to be deregulated in FOXN3deficient cancer samples, have a Forkhead Box binding site in their promoter, or are
known interaction partners of checkpoint proteins. We were able to shown that cyclindependent kinase 2 (CDK2) and Cyclin-B1 levels in FOXN3-deficient HCT116 cells
were lower than their Firefly-luciferase (control) transfected cells. Meanwhile, other
proteins levels like Cyclin-D1, Retinoblastoma, and Cdc2 (CDK1) were not changed due
to FOXN3 deficiency. This contradicted a previous report which showed con-committal
reduction of FOXN3 and CDK1 in oral cancers (167). Arguably, analysis done on oral
cancer samples can have different driver mutations that can perturb other pathways
leading to deregulation of CDK‟s and other checkpoint proteins (168). Meanwhile, our
system ascertains the expression of proteins due to reduction of FOXN3 only in a more
controlled experimental setting. Yet, a deeper look into the redundant and cooperative
mechanisms of cyclins and CDKs can shed some light on this contradiction.
Regulation of the cell cycle is an essential process in maintaining cellular
homeostasis and regulation of cell proliferation. At the epicenter of cell-cycle control are
heterodimeric protein kinases composed of a catalytic subunit, the Cyclin-dependent
kinase (Cdk), and a regulatory subunit known as Cyclin (169). Each family of cyclins
binds to a specific Cdk, forming a complex that is active at a specific phase of the cell
cycle. Progression of the cell-cycle is driven by sequential activation of several Cyclindependent kinases (Cdk), but mainly Cdk4, Cdk6, Cdk2 and Cdk1. Cues to initiate cell
division come from mitogenic factors (IGF-1, MAPK pathway) to induce expression of
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cyclin D and thus stimulate the activities of its binding partners Cdk4 and Cdk6 (170).
Increasing accumulation of cyclin D/Cdk4, Cyclin D/Cdk6 and cyclin E/Cdk2 complexes,
along with proliferating cell nuclear antigen (PCNA) coordinate DNA replication and
transition the cell into S phase entry. G2/M transition is regulated by cyclin A/Cdk2 and
cyclin B/Cdk1 complexes. Additional factors termed „cyclin-dependent kinase inhibitors‟
(CKIs) further control cell cycle progression; p27KIP1 and p21CIP1are examples of CDKI‟s
that bind to CDKs and prevent their activation. Some of these CDKI‟s are controlled by
tumor suppressor proteins like p53, which can arrest cell cycle progression at any stage
to ensure proper proliferation (171). Recent studies in different Cdk knockout mice have
shown redundancy in Cdk function and compensation by other complexes to promote
cell division. Mice lacking Cdk4 and Cdk2 complete embryonic development but die
shortly thereafter presumably; however, conditional ablation of Cdk2 in adult mice
lacking Cdk4 does not result in obvious abnormalities (172). Cdk2 and Cdk4 are
required to phosphorylate Retinoblastoma (Rb), a protein essential for G1/S cell cycle
progression. Additionally, Cdk2 and Cdk4 cooperatively regulate the expression of Cdc2
(CDK1), which cannot compensate for the loss of CDK2 during embryogenesis (170).
Recent work has also shown that Rb/Cdk2/Cdk4 triple mutant MEFs sustain enhanced
S-phase entry and proliferation rates similar to wild type (173).
Taken together, the loss of CDK2 could have been compensated by CDK4 or RB to
progress cells through the G1/S transition. Meanwhile, Cyclin-B1 interacts with CDK1 at
G2/M during transition into G2/M phase of the cell cycle and brings the onset of mitosis
(174). G2/M phase possesses a complex regulatory network of proteins that ensure
proper entry into this phase and proper mitosis. FOXN3-mediated loss of cyclin-B1 can
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potentially drive cells into G2/M without any regulatory input from CDK1, thus explaining
the cell proliferation seen in Foxn3 heterozygous mutant MEFs. Additionally, a Cyclin
A/Cdk2 complex regulates the activation of Cdk1 and Cdc25 (175). This provides
another potential link to the role of FOXN3 in regulating the activation of CDKs and
controlling cell cycle proliferation, a hallmark of cancer.
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Chapter IV
Chromatin Remodeling Proteins and The Role of CHD2 in Tumorgenesis
Chromatin and Nucleosome Dynamics
DNA in the eukaryotic cell is organized into a hierarchical structure called
„chromatin‟. Nucleosomes are the fundamental units of the chromatin and they consist
of 146 base pairs of DNA wound around a histone octamer. The histone octamer is a
positively charged protein unit that wraps the negatively charged DNA around it to
condense the DNA. The histone octamer consists of two molecules of each of the
histones H2A, H2B, H3, and H4 (176). This initial nucleosome organization forms a 10nm fiber known as “beads-on-a-string”. The binding of the linker histone H1 to the 10nm fiber allows for organization of the nucleosome arrays into a 30-nm chromatin fiber
(177). Higher-order compaction of DNA involves the „structural maintenance of
chromosomes‟ proteins (SMC) which include condensin and cohesin (178). Intrinsic
functions of the cell, such as DNA replication, transcription, and DNA repair require
accession of DNA sequences by DNA binding factors at proper regions and during the
appropriate times, however the compaction of DNA into chromatin makes it inaccessible
to such factors. To overcome this problem, a multitude of factors including histone
modifying enzymes and chromatin remodeling complexes work together enhance
accessibility of DNA regions to their specific factors. These chromatin modifying
proteins regulate the dynamics of nucleosomes, enabling the cell to perform its
functions.
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Histone modifying proteins
Histones, the protein component of the nucleosome, form two H2A-H2B dimers and one
H3-H4 tetramer that form the two nearly symmetrical halves of the histone octamer.
Histones fold into a helix-turn-helix region that composes the core of the histone and
also contain an N-terminal tail that protrudes outside the compact histone core.
Histones are subjected to posttranslational modifications at their N-terminal tails that
affect the affinity of DNA wrapping around the histone octamer (179). These posttranslational modifications include methylation, acetylation, phosphorylation,
ubiquitination, SUMOylation, ADP-ribosylation, and other modifications. These
modifications regulate the DNA at a „higher level‟ than the underlying DNA sequence;
the term “Epigenetics” or “histone code” has been given to these modifications (180).
The two best-studied modifications are methylation and acetylation.
Histone methylation of arginine and lysine residues is a major determinant for
formation of transcriptionally active and inactive regions of the genome as well as the
state of chromatin compaction. Arginine mono or di-methylation of histones H3 (Arg2,
17, 26) and H4 (Arg3) promotes transcriptional activation and a more loose chromatin
(181-183). This methylation is mediated by the protein arginine methyltransferases
(PRMTs) family that includes the co-activators PRMT1 and CARM1 (PRMT4) (184). In
contrast, histone lysine methylation is a more diverse and a better studied histone
modification. Lysine methylation is associated with both transcriptional activation as in
histone H3 (Lys4, 36, 79) and silencing as in histone H3 (Lys9, 27) and histone H4
(Lys20) (185). Tri-methylation of histone H3 (Lys9, 27) is associated with
heterochromatin, a region of highly compacted DNA with no active transcription.
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Additionally, methylated lysine histone tails can recruit proteins like HP1 (utilizing their
chromodomains) to propagate the methylation pattern to nearby histones, leading to
heterochromatin formation. The majority of lysine methyl-transferases identified thus far
contain a conserved catalytic SET domain originally identified in the Drosophila
Su[var]3-9, Enhancer of zeste, and Trithorax proteins (186). Conversely, methylated
histones can become demethylated if acted upon by a group of enzymes that include
the amine oxidase LSD1 (lysine specific demethylase 1), hydrolase JmjC (Jumonji) and
the arginine deaminase PAD4 (peptidyl arginine deiminase 4) (187). These enzymes
can remove methylated lysine or arginine residues (mono or di-methylated) and thus
can act as transcriptional repressors or activators, depending on the demethylated
residue.
Histone acetylation of lysine residues is another major epigenetic marker typically
associated with active transcription and loose compaction of DNA around the histone
octamer. Acetylation neutralizes the overall positive charge of the lysine residue, thus
reducing the affinity and weakening the binding between negatively charged DNA and
positively charged histones. Acetylation of histone H3 (Lys9) and histone H4 (Lys5, 8,
12, 16) are known markers for euchromatin, a region of lightly compacted chromatin
associated with active transcription (188). Not only does histone acetylation loosen the
DNA compaction, but it also helps recruit bromodomain-possessing proteins involved in
transcription. Acetylation of histone H3 (Lys9, 14) recruits the TFIID of the RNA
polymerase, while acetylation of histone H4 (Lys8) recruits the SWI/SNF complex (189).
Histone acetyl-transferases (HAT) are the family of enzymes responsible for histone
acetylation at lysine residues. The transcriptional coactivator families MYST,
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Gcn5/PCAF, and CBP/p300 compose the main three families of HAT, but are also
capable of acetylating other transcription factors like p53 (64, 190). Histone
deacetylases (HDACs), on the other hand, remove the acetyl group from lysine residues
of histones and promote compaction of DNA. The transcriptional co-repressor complex
Mi2/NuRD, mSin3a, and NCoR/SMRT recruit HDAC1, 2, and 3 respectively to deacetylate histones and compact the genome (191, 192).
ATP-dependent chromatin remodeling factors
Nucleosomes can be actively modified through ATP-dependent protein
complexes that utilize the energy from ATP hydrolysis to physically slide or remove
histones and nucleosomes (193). The common feature of the ATP-dependent chromatin
remodeling complexes is a highly conserved SNF2-related ATPase domain present in
four main classes and variations: The switching/ sucrose non-fermenting (SWI/SNF),
imitation switch (ISWI), INO80, and chromodomain helicase DNA binding (CHD), which
will be discussed in greatest detail. The INO80 complex is a conserved protein complex
composed of the Ino80 ATPase subunit, two AAA+ ATPases (Rvb1/2), Actin and its
related proteins Arp4, 5, and 8 (194). The Ino80 ATPase subunit provides the energy for
chromatin remodeling through nucleosome sliding. The INO80 complex interacts with
transcription factor Ying Yang 1 (YY1), linking INO80 to both activation and repression
of transcription. Additionally, INO80 is recruited to DNA double stand breaks (DSBs) in
yeast through interactions of its Arp4p and Nhp10p subunits with the phosphorylated
H2AX (γ-H2AX) histone variant present at the DSB site. The Drosophila ISWI is another
member of the SNF2-related family of ATPases, and it is the catalytic core of three
chromatin remodeling complexes: NURF, CHRAC, and ACF (195). Residues 16-19 of

81

histone H4 have been shown to be required for stimulation of ISWI ATPase activity,
which in turn repositions nucleosomes along DNA in cis (196).
The Swi2/Snf2 is the third class of SNF2-related ATPases and is the main
catalytic subunit of the yeast SWI/SNF complex. SWI/SNF protein complex interacts
with GAL4, a sequence-specific transcription factor, and mediate transcription in yeast
(197). Homologous subunits to the ATPase domain have also been identified in S.
cerevisiae (the RSC complex), Drosophila (BAP and PBAP), and at least two
complexes in mammals including the BRG1-associated factor complex (BAF), and the
polybromo BRG1-associated factor complex (PBAF; homologous to S. cerevisiae Rsc)
(198, 199). While SWI/SNF complex mediates transcriptional activation in yeast,
mammalian SWI/SNF complexes contribute to both repression and activation. During
mammalian T lymphocyte development, BRG1 is required to activate CD8 expression
and silence CD4 simultaneously (200). The flexibility of SWI/SNF complexes lies within
their ability to utilize ATP-dependent chromatin remodeling while also recruiting histone
deacetylases (HDACs), thus removing the transcriptional activating acetyl marks from
histone tails. ATP-dependent chromatin remodeling involving SWI/SNF complexes is
initiated through binding of the complex to nucleosomal DNA, followed by disruption of
histone-DNA binding, and ATPase subunit mediated translocation of DNA from histones
(198). This forms a DNA loop that can then be propagated through sliding or removal of
adjacent nucleosomes to generate stretches of DNA that are more accessible to DNA
binding factors.
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The CHD family of chromatin remodeling proteins
The chromodomain helicase DNA-binding proteins (CHDs) are an evolutionary
conserved family of proteins associated with chromatin remodeling (201). Members of
the CHD family of proteins are present in all eukaryotic organism; nine CHD family
members have been characterized in vertebrates. The CHD family is divided into three
subfamilies depending on the presence of additional motifs and the chromodomain
subclass. CHD1 and CHD2 belong to Subfamily I; CHD3 and CHD4 belong to
Subfamily II, while CHD5 through CHD9 belong to Subfamily III. CHD family proteins
are characterized by the presence of two chromodomains (Chromatin organization
modifier), DNA-dependent SNF2-related ATPase domain, DNA-binding domains (HMG1, PHD Zn-finger) and C-terminal helicase domain. The chromodomain is a 40-50
amino acids motif that binds to methylated lysine residues in the N-terminal tails of
histones, thus recognizing epigenetic marks laid out by histone modifying enzymes
(202). This domain is present in many proteins involved in chromatin remodeling
(Drosophila heterochromatin protein 1, HP1), heterochromatin formation (Polycomb),
and regulation of gene expression (RBP1) (203). The chromodomain is formed through
a hydrophobic core and hydrophobic groove required for interaction with tri-methylated
lysines and dimerization. The SNF2-related ATPase domain is a ~400 amino acids motif
that possesses an N-terminal ATP-hydrolysis domain and a C-terminal transduction
domain. Proteins that possess SNF2-related ATPase domain can disrupt nucleosomes
by either dissociating and/or repositioning (RSC and SWI/SNF), generating ordered
arrays of nucleosomes (Chd1 and ISWI), or facilitating the exchange of histones with
histone variants of a nucleosome (INO80 and SWR1) (204). CHD proteins mediate
chromatin remodeling by first binding to either DNA using their DNA-binding domain, or
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methylated histone tails using their chromodomain, and then activate their SNF2-related
ATPase/helicase domain (205). Activated ATPase domain facilitates ATP-dependent
translocation of the protein along DNA, thus generating force that can be directed into
arranged movement or destabilization of nucleosomes.
CHD Subfamily I
CHD subfamily I consists of two proteins: CHD1 and CHD2. Murine CHD1
protein was isolated from cDNA libraries of mouse lymphoid cell mRNA and encodes a
197-kDa protein characterized by the presence of chromodomain, a SWI2/SNF2 like
helicase domain, and its ability to bind immunoglobulin promoter sequence (206). CHD1
homologues were identified in most eukaryotic organisms with conserved domain
across all species. CHD1 has a pair of N-terminal chromodomains followed by SNF2related ATPase/helicase domain, a C-terminus helicase domain, and a Myb-related
DNA binding domain (201, 207). The human CHD1 is 95% homologous with murine
Chd1at the amino acids level and its chromodomains have been shown to bind
methylated lysine 4 in the histone H3 tail (H3K4) (204). This provides a mechanism that
targets CHD1 to transcriptionally active chromatin, as marked by trimethylated H3K4
(208). However, the two chromodomains of yeast Chd1 cannot bind to methylated H3K4
peptides, and in Drosophila the chromodomains are not required for the chromatin
localization of CHD1. The other possible mechanism of CHD1 localization to sequence
specific regions lies within its C-terminal DNA-binding domain. Studies on murine Chd1
identified a region of ~250–300 amino acids in its C-terminus that are required for
proper association with DNA and chromatin (204). Further analysis of the domain
revealed two main motifs similar to the SANT domain (SWI3, ADA2, NCoR, and TFIIB)
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and the SLIDE (SANT-like ISWI domain) domain. The Myb DNA binding domain is a 53
amino acids domain that forms a helix-turn helix motif characterized by the presence of
aromatic residues (209).
CHD1 has been shown to interact or be a component of many protein complexes
in depending on the organism. CHD1 has been shown to interact at the Drosophila‟s
polytene chromosome with the nuclear protein structure-specific recognition protein 1
(SSRP1), which plays a role in homologous recombination-mediated DNA damage
response (210). The majority of Chd1 studies were conducted in S. Cerevisiae, where
Chd1 was shown to interact with Rtf1, a component of the Paf1 complex that interacts
with the RNA Polymerase II and regulates transcription elongation (211). Chd1 has
been identified as a component of the yeast SAGA/SLIK (Spt, Ada, Gcn5
acetyltransferase / SAGA-like) complex (212). Murine Chd1 interacts with hormone
nuclear receptor corepressor (NCoR), thus suggesting a role for mouse Chd1 as a
transcriptional repressor. Moreover, yeast Chd1 antagonizes the yeast „facilitates
chromatin transcription‟ complex (yFACT), which contains the SSRP1 homologue
(Pob3) (213). FACT complex facilitates TATA-Binding Protein (TBP) and TFIIA binding
to nucleosomal binding sites in addition to its role in transcription elongation.
The other member of the CHD Subfamily I CHD2 shares ~60% similarity with
CHD1 at protein level with the least degree of homology at the N and C-termini that lack
conserved domains. CHD2 will be discussed in greater details in „Preliminary data‟.
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CHD Subfamily II
CHD subfamily II consists of two proteins: CHD3 and CHD4, also known as Mi2α and Mi-2β, respectively. Mi-2 proteins are present in the animal and plant kingdoms,
but are absent in yeast. CHD3 and CHD4 were initially identified as autoanitgens in the
connective tissue of patients with the autoimmune disorder dermatomyositis (214).
Biochemical analysis of Hela cells identified Mi-2α/β as a major component of the
vertebrate Mi-2/NuRD (Nucleosome remodeling deacetylase) complex, a multi-subunit
protein complex containing both histone deacetylase activity (HDAC1/2) and ATPasedependent nucleosome remodeling activity. In addition to the Mi-2 proteins and
HDAC1/2 proteins, the NuRD complex contains either one of the metastasis-associated
proteins (MTA1, 2, 3), methyl CpG-binding domain-containing protein 3 (MBD3), and
the retinoblastoma-associated proteins 46/48 (RbAp46/48) (214). The NuRD complex
possesses seemingly contradictory activities in HDAC, which deacetylate histone tails to
repress transcription, and ATPase nucleosome remodeling activities, typically
associated with activating transcription. However, the NuRD complex is associated with
transcriptional repression and can be targeted to different genes depending on the
identity of the MTA protein (215). MTA1 has been shown to repress estrogen receptorassociated transcription and interacts directly with ER in breast cancer cell lines and
affect ER-mediated BRCA1 gene transcription. Meanwhile MTA3 was shown to regulate
Snail transcription and interact with its promoter in-vivo (215).
Differently from the CHD subfamily I that possess the C-terminal HMG-1 (Mybrelated) DNA-binding domain, Mi-2 proteins have a plant homeodomain (PHD) as the
DNA-binding domain located in the N-terminus of the proteins. The PHD domain is
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homologous to the leukemia associated protein (LAP) and contains a RING domain
(Cys3-His-Cys4), a Zinc-finger like domain that binds DNA to activate transcription (216).
However, activation of ATPase activity of Mi-2 proteins is stimulated by binding
chromatin, not by free DNA or histones (214).
CHD Subfamily III
CHD subfamily III consists of five proteins: CHD5 through CHD9. CHD subfamily
III proteins have the two chromodomains, ATPase/helicase domain, and the C-terminal
helicase domain; moreover, they possess additional domains like a paired BRK
(Brahma and Kismet) domain, a CR domain, SANT-like domains, and a DNA-binding
domain (217). CHD subfamily III proteins have been identified in higher eukaryotes and
studied mostly in mammals and to some extent in Drosophila. CHD5 has two PHD Zinc
finger-like domains and a DEAD-box helicase domain associated with RNA-dependent
helicase/ATPase activity. Human CHD5 protein is expressed in neural-derived tissues
and was identified in patients with neuroblastoma (217, 218). CHD5 is located on the
chromosomal locus 1p36, a region commonly deleted in neural, epithelial and
hematopoietic cancers (219). CHD5 was proposed to function as a tumor suppressor
protein because Chd5-compromised cells (thus termed due to rearrangement or
deletions) had reduced expression of p16 Ink4a, p19Arf, and p53. CpG mediated
hypermethylation of CHD5 promoter was found in human cancers including gastric and
ovarian cancer, and also in squamous cell carcinoma cell lines (220, 221).
CHD6 is a ubiquitously expressed protein and a component of the PRIC complex
(PPARα-interacting cofactor) through interaction with PPAR protein (222). CHD6 also
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interacts with the transcription factor Nrf, which is implicated in cellular respiration
homeostasis, cell growth and heme biosynthesis (223). Additionally, CHD6 was shown
to co-localize with active RNA polymerase, but not a strong physical interaction. CHD6
has a DNA binding domain that has an affinity for A+T rich DNA (AT hook).
CHD7 is also a ubiquitously expressed protein first identified as a genetic
mutation in CHARGE syndrome patients (224). Additional studies using mouse models
with mutant Chd7 gene phenocopied CHARGE syndrome with mice exhibiting heart
defects, atresia of the choanae, and prenatal death (225). In a study to analyze CHD7
chromatin localization in mouse embryonic stem (ES) cells using a ChIP-Seq strategy,
CHD7 was shown to localize with ES cell master regulators OCT4, SOX2, and NANOG
(226). Additionally, CHD7 interacts with and co-localizes with P300 binding sites, a
component of the P300/CBP (CREB-binding protein) which functions as a HAT and a
known enhancer-binding protein complex.
CHD8 was first identified as a protein that interacts with the insulator binding
protein CTCF at its target site „differentially methylated region‟ (DMR) of H19. siRNA
mediated CHD8 knockdown abolished CTCF-mediated insulator activity, as the
expression of the H19 locus gene IGF2 was increased (227). Additionally, knockdown of
CHD8 affected CpG hypermethylation, histone acetylation, and heterochromatin
spreading around the CTCF binding sites of BRCA1 and c-Myc genes. Moreover, CHD8
interacts and negatively regulates β-catenin of the canonical Wnt signaling pathway, as
shown by increased β-catenin target gene expression in response to loss of CHD8
(228). In a study of CHD8 function in mice, Chd8−/− embryos die in utero between
embryonic day E5.5 and E7.5 due to widespread apoptosis (229). Further investigation
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showed an interaction of CHD8 with the tumor suppressor p53 and histone H1.
Depletion of CHD8 or histone H1 resulted in p53 activation and apoptosis, and CHD8
promoted histone H1 binding with p53 promoter to form a trimeric complex and inhibit
p53-dependent transactivation of its target genes.
The last member of CHD subfamily III proteins, CHD9, was first isolated as a
chromatin-related mesenchymal modulator (CReMM) from mesenchymal stromal cells
(MSC) (230). Murine CHD9 expression is restricted to marrow stromal progenitor cells
during the embryonic development of the mouse skeletal system by binding osteocalcin,
collagen-II, myosin, and CBFA1 promoters which affect tissue specificity (217).
Chromodomain Helicase DNA Binding Protein 2 (CHD2)
CHD2 is the second member of the CHD subfamily I proteins and shares 59%
homology and 70% identity with CHD1. Human CHD2 is located on chromosome
15q26.1 and encodes an 1828 amino acids protein with a proposed splice variant of
1739 AA protein (Ensembl: ENSG00000173575), while the murine CHD2 is located on
chromosome 7D1 and encodes an 1827 amino acids protein (Ensembl: ENSMUST00000169922). CHD2 has two N-terminal chromodomains, a central SNF2-related
ATPase/helicase domain, a C-terminus helicase domain, a Myb-related DNA binding
domain, and a C-terminal HMG-I domain (A+T hook). CHD2 is a poorly characterized
nuclear protein without biochemical analysis of its chromodomains and DNA binding
domains. The function of CHD2 is predicted from its homologue CHD1 and a few
reports in the literature. The human CHD2 chromodomain has a 30 fold weaker
interaction with the H3K4Me3 modified histone than human CHD1 (208). A microarray
profile study showed that CHD2 was down-regulated in blood cells of urinary bladder
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cancer patients compared to healthy controls (231). A study utilizing comparative
genomic hybridization revealed a homozygous deletion at chromosomal locus 15q26.2
(encodes CHD2 and RGMA) in the Hodgkin‟s lymphoma cell line HDLM2 (232). Two
recent studies revealed that Chd2 is important for mouse embryo development and
survival, and Chd2 mutant mice have impaired kidney function (126, 233). Additionally,
Chd2 mutant mice develop spontaneous lymphomas and lymphoid hyperplasias. Chd2
mutant mice also exhibit defective hematopoietic SC differentiation and defective DNA
damage response (126).
Chd2 mouse models
In an effort to understand the role CHD2 in mammalian development, Chd2
deficient mice were generated in our laboratory using the Baygenomics gene trap
embryonic stem cell resource. The Baygenomics insertional mutagenesis strategy
involves the use of a gene-trap cassette consisting of a splice-acceptor-βgeo cassette
(β-galactosidase-neomycin fusion gene) and characterized using 5‟ RACE (123). We
obtained one of the ES cell clones that had been characterized to have a gene trap
insertion within the Chd2 gene for analysis of the gene trap insertion site. Using multiple
intronic forward primers and a gene-trap specific reverse primer for PCR amplifications
and sequencing, we determined the gene-trap insertion site to be in intron 1 (Figure 17).
Chd2-targeted ES cells were used for blastocyst injections using the microinjection
services at the University of Massachusetts Medical School, Worcester. The colonies
from germline founders were further expanded for the analysis of the mutant offspring.
This mouse model was termed N-terminal Chd2 mutant and differs from the C-terminal
mouse model previously generated and characterized (126). The working model for the
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Baygenomics gene traps encompasses the splicing of the 5‟ splice site of Chd2‟s exon
1 (encoding 20 amino acids) into the 3‟ splice site in the gene trap (Figure 16). This
allows for the in-frame fusion of the first two exons of Chd2 to the B-galacotsidase
neomycin sequence and the expression of this fusion protein. The expression of this
fusion protein is mandated for the blastocysts to survive neomycin selection. Upon
efficient splicing of the Chd2 gene into the gene trap, the remainder exons will not be
translated and thus the wildtype protein will be haplo-insufficient in heterozygous
progeny and completely lost in nullisomic progeny.

En2

Chd2

SA

β-Geo

Exon 1

En2: Engrailed 2 intron sequence
β-Geo: β-gal-neomycin fusion gene

SV40pA

Gene trap

Exon 2

SA: Splice Acceptor site
SV40pA: SV40 poly A

Figure 16.Schematic representation of the Baygenomics gene trap integrated into intron 1 of Chd2 gene.
The gene trap cassette contains an Engrailed 2 intronic sequence followed by a splice acceptor
site, an ATG-less B-galactosidase neomycin fusion gene and a ploy-A site.
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Figure 17. Schematic representation of the strategy utilized to configure the gene-trap insertion site in
intron 1 of the Chd2 gene. Chd2 Intron 1 forward primers were designed at 2kB space intervals and
tested against one gene-trap specific reverse primer in WT and Heterozygous mice. Sequencing of
the PCR product indicated that the gene trap was integrated within intron 1 (13.9KB from the
beginning of the intron) of the Chd2 gene.

Materials and Methods
Reagents and Antibodies
Cell culture reagents were obtained from the following sources: fetal calf serum and
Antibiotic-Antimycotic (Gibco, Invitrogen),5-Flurouracil & Doxorubicin (Sigma).
Antibodies were obtained from the following sources: CHD2 (Dr. Venkatachalam‟s lab,
University of Tennessee); p53-K382 Acetylated, H3K9 Acetlated, H4K8 Acetylated (Cell
Signaling Technology, Danvers, MA, USA); Beta-Tubulin (Gentex, Zeeland, MI); Puma (
Calbiochem, Gibbstown, NJ); p21, p53 (FL-393X) (Santa Cruz Biotechnology, Santa
Cruz, CA).
Western Blot
HCT116 cells were scraped in phosphate-buffered saline (PBS), pellet at 1‟400 RPM,
and lysed in BE lysis buffer plus 1mM PMSF (40mM NaCl, 20mM Tris-HCl pH 7.8, 2mM
MgCl2, 0.5% NP40, Benzonase (Novagen, 250U/mL)). Cell lysates were mixed with
reducing Laemmli sample buffer, separated on 8% or 12% SDS–polyacrylamide gels
and transferred onto PVDF membranes (Thermo scientific). Membranes were blocked
92

at room temperature for 2 hours in TBS-Tween (100mM Tris-HCl, 200mM NaCl, 0.1%
Tween 20) with 5% milk, and incubated with primary antibody overnight at 4 oC or at
room temperature for 2 hours. After washing with TBS-T, membranes were incubated
with horse radish peroxidase-conjugated secondary antibody for 1 hour at room
temperature in TBS-T containing 2% milk. Signal was visualized with the Super Signal
chemiluminescent reagent (Thermo scientific).
RNA isolation and RT-PCR protocol
Total RNA was extracted using Trizol according to the manufacturer‟s instructions
(Invitrogen) from adult thymus (6 weeks of age). First strand cDNA synthesis was
performed with 2µg of total RNA (pretreated with RNAse free DNAse) with random
hexamers and M-MLV reverse transcriptase (Promega) for 1 hour at 42oC followed by
inactivation of the reverse transcriptase at 70 0C for 15 minutes. A similar amount (2µg)
of total RNA (pre-treated with RNAse free DNAse) was subjected to the above
mentioned conditions in the absence of M-MLV reverse transcriptase. For PCR assays,
2µl of the reaction mixture (from a total of 40 µl) obtained from the first strand cDNA
synthesis reaction was used. The PCR conditions were 94 0C for 2 min, followed by 30
cycles at 940C for 30 sec, 580C for 30 sec and 720C for 10 sec. PCR products were
resolved by agarose gel electrophoresis and stained with ethidium bromide. For
Chromatin Immunoprecipitation isolated DNA, 2.5µL of DNA eluant were subjected to
primer specific amplification, and the PCR conditions were 94 0C for 2 min, followed by
40 cycles at 940C for 30 sec, 590C for 30 sec and 720C for 5 sec.
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Quantitative PCR
The real-time PCRs were performed on a Bio-Rad iQ5 system using TaqMan® Gene
Expression Assays (Applied Biosystems, Foster City, CA). Gene-specific primers were
obtained from Applied Biosystems (Mm00519268_m1 for Puma, Mm01197698_m1for
Beta-Glucuronidase). Puma expression values (Ct-values) were normalized to the mean
expression value of the housekeeping genes Beta-Glucuronidase to obtain relative
expression levels using the 2-ΔΔCt. All reactions were performed in triplicate.
Chromatin Immunoprecipitation
HCT116 cells were scraped and crosslinked with 1% formealdehyde (Fisher) in ChIP
Buffer (60mM KCl, 15mM NaCl, 4mM MgCl 2, 15mM HEPES pH 7.6, 0.5% Triton X-100,
10mM Sodium Butyrate) for 20 minutes at room temperature with rotation. For Mouse
thymocytes: 6 weeks old mice were sacrificed, thymus was isolated and cells were
strained using a 0.45µM strainer, cells were then crosslinked with 1% Formealdehyde in
ChIP buffer. Samples were then neutralized with 300mM Glycine for 10 minutes,
washed twice with ChIP Buffer, and lysed with ChIP LB (140mM NaCl, 15mM HEPES
pH7.6, 1mM EDTA, 1% Triton X-100, 0.1% Sodium Deoxycholate, 10mM Sodium
Butyrate, Protease Inhibitors (Roche), 5µM Trichostatin A) for 10 minutes. Samples
were sonicated to obtain 500-1000BP DNA fragments and then pre-cleared with
Protein-G agarose beads overnight at 4oC. Pre-cleared samples (1.5mg) were then
incubated with primary antibody (4µg) for 6 hours at 4 oC and then fresh Protein G
agarose beads were added to samples and rotated overnight at 4 oC. The
Immunoprecipitates were washed successively with low salt buffer (20mM Tris-HCl [pH
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7.8], 150mM NaCl, 0.1% SDS, 1% Triton X-100, 2mM EDTA), high salt buffer (20mM
Tris-HCl [pH 7.8], 500mM NaCl, 0.1% SDS, 1% Triton X-100, 2mM EDTA), LiCl
washing buffer (10mM Tris-HCl [pH 7.8], 250mM LiCl, 1% NP40, 1% Sodium
Deoxycholate, 1mM EDTA), and TE Buffer. DNA-protein complex were eluted with IP
elution buffer (1% SDS, 0.1M NaHCO3), reversed crosslink by adding 200mM NaCl and
incubating eluant at 65oC. Protein and RNA was digested by adding Proteinase K and
RNase A, respectively and DNA was extracted using GeneJET kit (Fermentas, Glen
Burnie, MD) and eluted with equal volume of nuclease-free water.
RNA Interference Transfection
RNAi oligonucleotides were obtained from IDT DNA (F-LUC-Si, CHD2si-2) or
Dharmacon (CHD2si, used in most experiments) and resuspended in nuclease-free
water to a concentration of 40µM. HCT116 cells were plated in 60mm-well plates in
DMEM media containing 10% fetal bovine serum to give 30–50% confluence.
Transfection of the RNAi oligonucleotides was performed using Trifectin (IDT-DNA) to
result in a final RNA concentration of 40 nm. The cells were harvested at different time
points and lysed in BE lysis buffer (above mentioned) for Western blot analysis. siRNA
sequences were:
F-Luc si: 5'-rGrCrA rUrArU rCrArA rArGrC rArCrA rUrCrA rGrGrU rCrCA C-3'
5'-rGrUrG rGrArC rCrUrG rArUrG rUrGrC rUrUrU rGrArU rArUrG rCrCrU-3'
CHD2si: 5' rUrUrA rGrArC rArUrU rGrGrG rArUrC rUrUrA rGrGrA rUrUrC rUrUrC 3'
5' rArGrA rArUrC rCrUrA rArGrA rUrCrC rCrArA rUrGrU rCrUA A -3'
CHD2si-2: 5'-rGA UAG CUG AUG UGA AGA AGA UGT G-3'

95

Results
4.1. Characterization of N-terminal Chd2 deficient mice.
The gene-trap in the Chd2 C-terminal model inserts in intron 27, thus retaining a
substantial portion of the Chd2 protein (translation of the first 1198/1828 amino acids).
This truncated protein retains all common CHD domains fused to the β-galactosidaseneomycin gene. This fusion protein may have a dominant negative effect, a gain of
function effect, or sequester the function of binding proteins necessary to mediate Chd2
activity. Therefore, we resorted to the Chd2 N-terminal mouse model (Here forth, the
only model studied) as a better alternative to study Chd2‟s function in mammalian
development, DNA damage response, and tumorogenesis. We analyzed the post-natal
lethality of Chd2 mutant mice. Analysis of Heterozygous matings at weaning (day 21)
shows a 27% survival of the null offspring, which indicates lethality of the Chd2 mutant
mice. The mutant offspring that survived beyond the perinatal stage did not show any
overt developmental abnormalities. However, after 5–12 months of age, the
heterozygous mice began to exhibit weight loss, lordokyphosis (hunch-back spine) and
loss of vitality. Survival analysis showed drastic reduction in the lifespan of the Chd2
heterozygous mice with a median lifespan of 59 weeks ( Figure 18)
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Figure 18. Chd2 deficiency leads to reduced lifespan in mice. Kaplan-Meier survival curves of Chd2
mutant and wild-type littermates (n=30). The percentages of survival are plotted as a function of age
in weeks. Animals were monitored for tumors, morbidity, or spontaneous death over a period of
120 weeks. Of the 30 animals analyzed for each group, all the heterozygous mutants have died in
comparison to 10 for the wild-type controls. The median lifespan of the Chd2 +/- mice was 59.35
weeks in comparison to 91.3 weeks in the wild type littermate controls. All mice were of mixed
inbred C57BL/6X129/Sv background.

Histological examination of organs harvested from morbid mice showed that a
majority of the mice were succumbing to splenic or thymic lymphomas or lymphoid
hyperplasias with a fraction of adenomas and sarcomas ( Table ). The earliest incidence
of lymphomas in the mutant mice was at 26 weeks of age. 53% of the heterozygous
mutants (16/30) exhibited spontaneous tumor formation. In comparison, only 25% of
wild-type mice were diagnosed with a tumor during the analysis period (4/12). Wild-type
mice also develop lymphomas as a function of age, and such tumors account for about
5–20% incidence as reported for mice of various genetic backgrounds by others.
Histological examination of organs also revealed Glomerulo-nephoropathies and
inflammation of the heart or arteries in a minority of the animals as well as Extra
Medullary Hematopoiesis (EMH) in 57% of the animals examined.
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Table 3. Distribution of pathological conditions in Chd2 deficient (N-terminal mutant) mice. Tissues from
a total of 30 mice (Chd2+/-) were analyzed to determine the reasons for morbidity. Hearts were
examined for 8 mice. To avoid over-estimation of lymphoid hyperplasias, animals exhibiting
lymphomas as well as lymphoid hyperplasias (in other organs) were categorized under
lymphomas. *15 out of 17 animals diagnosed with EMH exhibited either lymphoid hyperplasia or
lymphoma. ** Both the animals exhibiting nephropathy were diagnosed with either lymphoid
hyperplasia or lymphoma. ***The animal diagnosed with heart inflammation exhibited either
lymphoid hyperplasia. ****Three animals were diagnosed with bronchoalveolar adenoma and two
were diagnosed with sarcomas.

Lymphoma

53% (16 of 30)

Lymphoid hyperplasia

36.6% (11 of 30)

Extra Medullary Hematopoiesis* (EMH)

56.6% (17 of 30)

Glomerulo-nephropathy**

10% (2 of 19)

Inflammation of heart/artery***

11% (1 of 9)

Other cancers****

16.6%

(5 of 30)

Since histological analysis of Chd2 heterozygous mice revealed thymic
lymphomas and thymic hyperplasias, we wanted to test whether Chd2 plays its greatest
role specifically in the thymus of mice. For that, we crossed Chd2 heterozygous males
with Lck-Cre transgenic founder female mice expressing Cre recombinase exclusively in
thymus. This leads to excision of the splice-acceptor site of the gene trap, thus
bypassing it and leading to wildtype expression of Chd2 in the thymus only (termed LYCre). Chd2 expression in the thymus restored normal life span of heterozygous mice to
that of wild type mice. Median lifespan for LY-Cre heterozygous mice was 102 weeks
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(n=8) compared to a median lifespan of 59 weeks for Chd2 heterozygous mice ( Figure
19).

Figure 19. Restoration of CHD2 expression in thymus restores normal life span of CHD2 heterozygous
mice. Kaplan-Meier survival curves of Chd2 mutant and wild-type littermates (n=8). The
percentages of survival are plotted as a function of age in weeks. Animals were monitored for
tumors, morbidity, or spontaneous death over a period of 120 weeks. The median lifespan of the
Chd2 +/- mice was 59.35 weeks in comparison to 102 weeks in the LY Cre Het mice. All mice were
of mixed inbred C57BL/6X129/Sv background.

To determine the mechanistic role of Chd2 in tumorogenesis, we tested the
fidelity of the cell cycle progression in wildtype and Chd2 mutant MEFs. Incorporation of
the thymidine analog, Bromodeoxyuridine (BrdU), indicates cell proliferation. Cells that
are treated with X-ray radiation arrest at the G1/S and G2/M boundaries and therefore
don‟t incorporate BrdU. Flow cytometry analysis indicates that Chd2+/m and Chd2m/m
keep incorporating BrdU 16 hours after treatment with X-ray radiation (Figure 20).
Furthermore, Chd2+/m and Chd2m/m do not arrest at the G2/M boundary either. This is
indicative of a cell cycle arrest deficiency which can be caused by the deregulation of
many gene including the cyclin-dependent kinase inhibitor 1 (p21/WAF1).
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Figure 20. Effects of Chd2 on Cell-cycle Arrest. DNA damage induces the cell-cycle inhibitor p21
causing arrest in the G1/S and G2/M phase. Wildtype cells exhibit cell-division arrest after
treatment with 4Gy X-Ray. Chd2 heterozygous and nullizygous MEFs exhibit a diminished G2/M
arrest and increased S phase synthesis.

4.2. Chd2 deficient thymocytes exhibit deficient Puma response.
Since many of the Chd2 heterozygous mice were succumbing to lymphomas and
lymphoid hyperplasias and hematopoietic deficiencies, we tested the ability of Chd2
mutant animals to undergo apoptosis. We picked the p53-upregulated modulator of
apoptosis (Puma) as a candidate gene to test its induction in wildtype and Chd2 mutant
thymocytes. RT-PCR analysis showed a severe deficiency in Chd2+/m and Chd2m/m
thymocytes‟ ability to induce Puma after DNA damage ( Figure 21). Q-PCR analysis
further confirmed our initial findings where Puma was 27 folds higher in treated wildtype
thymocytes over the untreated control ( Figure 22). Meanwhile, Puma was only 2.5 and
1.3 folds higher in treated Chd2+/m and Chd2m/m thymocytes over the untreated
control respectively.
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Figure 21. Expression of PUMA in Chd2 Thymocytes. Chd2 thymus were isolated and total RNA was
harvested 3H after 6Gy X-ray treatment. RT-PCR analysis show no induction of the p53upregulated modulator of apoptosis (PUMA) in Chd2 deficient mice.
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Figure 22. Real-Time analysis of PUMA levels in Chd2 thymocytes. Wildtype Thymocytes show a 27
fold induction of Puma three hours after treatment with 6Gy X-ray. Chd2 heterozygous and
nullisomic thymocytes exhibit a lack of induction after DNA damage. B-Glucuronidase (GusB) was
used as an internal control.
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4.3. CHD2 deficient cells exhibit reduced PUMA induction
RNA interference was effective in reducing CHD2 protein levels in HCT116 cells.
CHD2 is not induced after treatment of cells with the thymidylate synthase inhibitor 5Flurouracil (Figure 23). Chd2 deficiency did not have an effect on the lysine 382
acetylation of p53 after 5FU treatment. However, Puma levels were greatly reduced in
CHD2 deficient cells compared to controls ( Figure 23). Additionally, p21 levels were also
reduced in CHD2 deficient cells, indicating an insufficient induction of these p53
regulated genes. Beta-tubulin indicates equal loading control of cell lysates ( Figure 23).
Since CHD2 appears to play a role in transcriptional upregulation of Puma, we wanted
to test whether CHD2 deficiency affects histone tail markers associated with
transcriptional activation. Acetylation of lysine 9 of Histone 3 (H3K9Ac) and acetylation
of lysine 8 of Histone 4 (H4K8Ac) are well known markers of active transcription. Global
acetylation of these two histones was reduced in untreated CHD2-deficient cells
compared to wild type cells (Figure 24). 5FU treated CHD2-deficient cells showed a
greater reduction of each of these marks compared to controls, thus further indicating a
deficiency in histone acetylation in CHD2-deficient cells. However, although PUMA was
not being induced, apoptosis was still proficient as indicated by cleavage of poly ADP
ribose polymerase (Figure 24). Same results were obtained using a second set of CHD2
siRNA, further supporting our findings.
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Figure 23. Western blot analysis of CHD2 deficient DNA-damage response in HCT116 cells. RNAi was used
to attenuate CHD2 protein levels. P53 acetylation at lysine 382 was not affected by CHD2 knockdown, yet levels
of the p53 target gene Puma were reduced in CHD2-deficient cells compared to control (F-Luc). P21, another p53
target, was also reduced in CHD2-deficient cells, but to a lesser extent. Beta-Tubulin shows equal loading.
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Figure 24. Western blot analysis of CHD2 deficient DNA-damage response in HCT116 cells. RNAi was
used to attenuate CHD2 protein levels. Levels of histone H3 (Lys9 acetylated) and histone H4
(Lys8 acetylated) were reduced in CHD2-deficient cells compared to control (F-Luc). The
apoptosis associated protein PARP levels remained similar in 5FU treated cells in both control
and CHD2-deficient cells. Beta-Tubulin shows loading control

4.4. CHD2 localizes to Puma in mouse thymocytes.
Based on these findings, we wanted to determine whether Chd2 plays a role in
the induction of Puma. We utilized chromatin immunoprecipitation (ChIP) to determine
whether CHD2 binds to the Puma promoter and the p53 response element there. Our
results initially indicated that Chd2 binds to the Puma promoter in wildtype thymocytes
(primers designed to amplify p53 RE located in Intron 1 of the Puma promoter)
specifically after DNA damage (Figure 25). Further experiments showed that Chd2 is
enriched at the Puma promoter after DNA damage. Moreover, we tested a region 1.5KB
upstream of the Puma promoter as an additional control and were able to amplify that
region, which could indicate the spreading of Chd2 throughout the region ( Figure 26).
However, CHD2 didn‟t localize to an unrelated gene HGPRT. We then tested whether
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Chd2 plays a role in the recruitment of p53 to its response element on the Puma
promoter. DNA analysis indicates that p53 is recruited to its cognate region sufficiently
in wildtype and Chd2 mutant thymocytes; furthermore, p53 is enriched at its Puma RE
after DNA damage, which is consistent with previous studies ( Figure 27).

Figure 25. Chromatin immunoprecipitation (ChIP) on wildtype thymocytes. DNA analysis on Chd2 IP
shows localization to the Puma promoter after DNA damage. 10% Input shows total lysate control.
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Figure 26. Chromatin immunoprecipitation (ChIP) on wildtype thymocytes. DNA analysis on Chd2 IP
shows localization to the Puma promoter. Lack of amplification of the HGPRT region indicates
specificity of Chd2 IP. 10% Input shows total lysate control. Upstream indicates the 1.5KB region
upstream of the Puma promoter.
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Figure 27. Chromatin Immunoprecipitation analysis on Chd2 Thymocytes. DNA analysis on Chd2 IP
shows localization to the PUMA promoter after DNA damage. p53 IP on WT and Chd2 nullisomic
thymocytes shows no role for Chd2 in localizing p53 to the PUMA promoter. 10% Input shows
total lysate control.

4.5. CHD2 localizes to Puma in p53-dependent manner in HCT116 cells.
In HCT116 wild type cells, CHD2 localizes to the p53 response element of the
Puma promoter before DNA damage, but is enriched there after DNA damage (Figure
28Figure 29). Moreover, Chd2 localizes to the p53 response element of the Puma

promoter in the thymocytes of wildtype mice. CHD2 localizes to other regions within the
Puma locus including Intron 3, which has been reported to be enriched in trimethylated
H3K9 histones and occupied by the insulator protein CTCF (234). Additionally CHD2 is
slightly enriched in the 5KB region upstream of the PUMA promoter after DNA damage,
indicating its ability to spread beyond the promoter (Figure 30). However, CHD2 doesn‟t
localize to the Beta-Glucuronidase promoter before or after DNA damage (Figure 31).
The tumor suppressor protein p53 also is enriched at the PUMA promoter, which has
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been established before. This enrichment of CHD2 in a manner similar to p53 at the
PUMA promoter led us to test whether p53 and CHD2 are co-dependent on each other
to be recruited to the PUMA promoter. For, we tested the localization of CHD2 to PUMA
promoter in HCT116 Null cells which lack p53. The localization of CHD2 to the Puma
promoter was reduced as indicated by the band intensity (Figure 29). Additionally, the
localization of CHD2 to the 5KB region upstream of PUMA promoter was greatly
increased after DNA damage in the p53 deficient cells. Moreover, CHD2 appears to
localize to the Beta-Glucuronidase promoter after DNA damage in p53 deficient cells,
indicating a possible role for p53 in guiding the localization of CHD2 (Figure 31). We
then tested whether CHD2 deficiency affects p53 localization to its cognate response
element in the PUMA promoter. P53 was enriched after DNA damage at the PUMA
promoter in CHD2 deficient cells but at lower intensity compared to wild type cells
(Figure 29). H3K9Ac markers enrichment at the Puma promoter appears to remain
unchanged in wild-type and CHD2-deficient cells (Figure 32). Although we have shown
that CHD2 deficiency reduces global acetylation, especially after DNA damage, it‟s
possible that Puma acetylation is not affected in this case, or that we acetylation of
Puma remains constant, while only CTCF mediates transcription of exon 3 to form the
functional mRNA (234). Three biological replicates were done for each ChIP.
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Figure 28. Chromatin Immunoprecipitation analysis of CHD2 localization to p53 response element in
Puma. DNA analysis on Chd2 IP shows localization and enrichment to the PUMA promoter after
DNA damage. CHD2 localization is reduced in HCT116 p53-/- cells as shown by reduced intensity
of bands. 1% Input shows equal total lysate control, and IgG ChIP shows antibody specificity.
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Figure 29. ChIP analysis of p53 localization to its response element in Puma. DNA analysis on p53 IP
shows localization and enrichment to the PUMA promoter after DNA damage. P53 localization is
reduced in HCT116 treated with CHD2-specific siRNA cells as shown by reduced intensity of
bands. 1% Input shows equal total lysate control, and IgG ChIP shows antibody specificity.
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Figure 30. ChIP analysis of CHD2 localization to a 5KB region upstream of Puma promoter. DNA analysis
on Chd2 IP shows localization of CHD2 to the upstream region of the PUMA promoter after DNA
damage. CHD2 localization is greater in HCT116 p53-/- cells as shown by increased intensity of
bands, possibly indicating a role for p53 in CHD2 localization. 1% Input shows equal total lysate
control, and IgG ChIP shows antibody specificity.
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Figure 31. ChIP analysis of CHD2 localization to an unrelated Beta-Glucuronidase promoter. DNA
analysis on Chd2 IP shows no localization of CHD2 to the Gus-B promoter in HCT116 cells. CHD2
localization to this region is seen in HCT116 p53-/- cells as shown by presence of bands, possibly
indicating a role for p53 in CHD2 localization. 1% Input shows equal total lysate control, and IgG
ChIP shows antibody specificity.
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Figure 32. ChIP analysis of Acetylated histone H3 (Lys9) localization to Puma promoter. DNA
analysis on H3K9Ac IP shows similar levels of localization before and after DNA damage at the
Puma promoter and in wild type and CHD2-deficient cells. 1% Input shows equal total lysate
control, and IgG ChIP shows antibody specificity.
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Discussion
Our results suggest an indispensible role for CHD2 in preventing tumorogenesis
and inducing Puma after DNA damage. Previous work in our laboratory had shown that
Chd2 mutant mice succumb to lymphomas and have a deficient DNA damage response
(126). However, our previous mouse model (C-terminal) expresses the first 27 exons of
Chd2, which encode for the chromodomain, SNF2-related helicase domain, C-terminal
helicase domain, fused to the neomycin-β-gal gene. This can potentially create a
dominant negative protein that can interact with wild type Chd2. Our current model (Nterminal) possesses the gene-trap after exon 1 (20 amino acids) of Chd2, thus creating
a superior hypomorphic model to study the role of Chd2. Similar to the C-terminal
mouse model, N-terminal mutant mice also exhibit reduced lifespan and spontaneous
lymphomas. However, the spectrum of tumors expands to include sarcomas and
adenomas (16.6% of mice), which was absent from the C-terminal model. Additionally,
restoration of Chd2 expression in the thymus of mutant mice restores their lifespan to
that of wild type littermates, thus suggesting that Chd2 plays its greatest role in the
thymus. We suspected Chd2 to play a role in DNA damage repair pathways and wanted
to test the effect of Chd2 deficiency on the induction of the cell-cycle progression gene
(p21) and apoptosis related genes (Puma, Noxa, Bax). Indeed, Puma induction both in
mouse thymus was reduced after X-ray irradiation in Chd2 deficient cells, indicating a
role for Chd2 as a transcriptional regulator of Puma induction. Because of the time
consuming nature of animal work and lack of reliable mouse specific antibodies, we
wanted to test the effect of CHD2 deficiency on PUMA induction in HCT116 cells.
HCT116 cells are epithelial colon cancer cells that are capable of undergoing apoptosis
when chemically stressed. Another advantage to using HCT116 cells is they are
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available in both wild type and p53 null lines. Therefore, we can test the effect of p53 on
a proteins function while maintaining every other pathway in the cell line. We tested
multiple chemical stressors in HCT116 cells to check the best induction of PUMA, and
concluded that 5-flurouracil is the best compound to induce PUMA. CHD2 deficient cells
exhibited reduced PUMA induction after treatment with 5FU. This pattern is similar to
the reduced Puma induction in Chd2 mutant mouse thymocytes. Interestingly, it
appears that apoptosis is not affected by the lack of PUMA induction as PARP cleavage
is similar in both control and CHD2-deficient cells treated with 5-FU. Since apoptosis is
induced by p53-dependent and p53-independent pathways (TNF-α, Fas- pathways), an
alternative pathway can possibly trigger apoptosis in the absence of PUMA induction
after DNA damage.
P21, another p53 target, was induced in CHD2 deficient cells after DNA damage
but a lower level than control cells, possibly indicating a role for CHD2 in the induction
of p53 target genes. In previous work, CHD8 was shown to affect the acetylation of p53
and the induction of its downstream targets; therefore, we wanted to test whether CHD2
deficiency affects p53 acetylation to possibly designate a mechanism of action for
CHD2 (229). Acetylation of p53 at lysine 382 of its C-terminal regulatory region has
been shown to enhance p53‟s activity as a transcription factor, allowing p53 to bind its
RE with a greater affinity. CHD2 deficiency did not affect p53 acetylation at Lysine 382
after 5FU treatment, thus indicating a different mechanism of action for CHD2 on
transcription activation. We next looked at CHD2‟s affect on Histone acetylation
because CHD1 has been shown to be a component of the SAGA histone
acetyltransferase complex (212). H3K9 and H4K8 acetylation are well known
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transcriptional activation markers (235). Histone acetylation at majority of genome is
reduced after DNA damage to allow the cell to resolve the damaged DNA before
continuing through the cell cycle. CHD2 deficient cells exhibit global reduction in H3K9
and H4K8 acetylation when comparing untreated cells (No DNA damage). After DNA
damage, H3K9 and H4K8 acetylation is reduced in control cells but is almost
undetectable in CHD2 deficient cells. This indicates a role for CHD2 in histone
acetylation and possibly preludes a mechanism for the lack of PUMA induction after
DNA damage.
We further verified a role for CHD2 in PUMA induction by checking CHD2
localization to the Puma locus using Chromatin Immunoprecipitation. DNA eluted from
CHD2 ChIP was amplified using specific primers to test the p53 response element of
the Puma promoter, a 5KB region upstream of this response element, a region of Intron
3 of Puma locus, and an unrelated Beta-Glucuronidase promoter (GusB). The 5KB
region and the Intron 3 test whether CHD2 spreads beyond the promoter of Puma, while
the GusB promoter works as a control of a housekeeping gene. CHD2 is enriched at the
p53 response element after DNA damage, but this enrichment is slightly reduced in p53
deficient HCT116 cells. CHD2 spreads to the 5KB region upstream of Puma promoter
and to Intron 3 after DNA damage, showing that it spreads all along a locus to remodel
chromatin. CHD2 is present in higher levels at the 5KB upstream region and is reduced
at the Puma promoter in p53 deficient HCT116 cells after DNA damage. This points to a
role for p53 in guiding CHD2 binding on the genome or at least laying the groundwork
for CHD2 binding through its chromodomain or its A+T hook DNA binding domain. Also,
CHD2 binds to the GusB promoter in p53 deficient cells after DNA damage; this is not

117

seen in wild type cells and further leads to a role for p53 in guiding CHD2 binding.
CHD2 deficiency also slightly reduces p53 localization to its response element after
DNA damage. This could be due to reduced global acetylation in CHD2 deficient cells,
which makes the chromatin more compact and less accessible to transcription factors.
We also tested whether CHD2 binds to p53 RE at the CDKN1A locus (p21 locus) and
indeed CHD2 is enriched there after DNA damage (Data not shown).
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